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Abstract 
The tumor suppressor p53 gene plays important roles in regulation of cell cycle and 
apoptosis when cells are under stresses like D N A damage. The gene is mutated in 
over 50% of human cancers. Mutation of the p53 gene appears as hot spots in the 
central D N A binding domain. Mutant p53 protein not only loses its tumor suppressor 
functions but also gains new functions in transregulating genes conferring increased 
malignancy in cancer cells. One of the major obstacles in cancer therapy is drug 
resistance. In this study, the role of mutant p53 in resistance to therapeutic agents 
was studied. 
Human osteosarcoma Saos-2 cells, a p53-null cell line, were transfected with p53 
with mutation at codons 143 (valine to alanine) (p53-V143A) and 273 (arginine to 
histidine) (p53-R273H). It was found that both mutant p53-V143A and p53-R273H 
transfectants were more resistant to interferon-alpha (IFN-alpha), interferon-gamma 
(IFN-gamma) and common chemotherapeutics such as camptothecin (CAM), 
methotrexate (MTX), tamoxifen (TAM) and vincristine (VCR) while p53-V143A 
transfectant was more resistant to taxol (TAX) when compared to the control cells. 
IFN-alpha and -gamma induced cell cycle arrest at G1 phase and D N A fragmentation. 
Mutant p53-V143A and p53-R273H transfectants were resistant to IFN induced 
apoptosis through activation of caspase cascade. IFN signaling involves the Jak/Stat 
pathway. Mutant p53-V143A and p53-R273H seemed to regulate the expressions of 
jaks and Stats in Saos-2 cells in a mutant specific manner. There was a 
downregulation of Jaks in mutant p53 transfectants, i.e. Tyk2 in p53-V143A and 
Tyk2 and Jak2 in p53-R273H. AG490, a Jak2 specific inhibitor, and Jak inhibitor I, 
an inhibitor of all four Janus kinases, made Saos-2 cells more resistant to IFN 
suggesting that Jaks may play a role in IFN sensitivity. However, AG490 failed to 
II 
modify the IFN induced D N A fragmentation but could modulate IFN activation of 
Jak/Stat pathway through phosphorylation of Jaks and Stats. 
Mutant p53 transfectants were resistant to D N A fragmentation and cell cycle arrest 
induced by the common anticancer drugs. Jaks were involved in C A M , M T X and 
V C R sensitivity while Jak2 was significantly involved in the M T X sensitivity in 
Saos-2 cells as AG490 made Saos-2 cells more resistant to M T X induced apoptosis 
through inhibition of caspase 3 activation. However, the Jak/Stat signaling failed to 
provide hint for the downstream target of Jak2 involved in M T X sensitivity. 
The present study sheds light on the role of mutant p53 in IFN and drug resistance. It 
may provide new target for cancer treatment and also better prognosis of different 
treatment for patients carrying a particular p53 mutation. 
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Chapter 1 General Introduction 
1 
1.1 The p53 tumor suppressor gene 
1.1.1 Structure and function 
The product of the p53 tumor suppressor gene was first identified as a tumor antigen 
that bound to simian virus 40 (SV40) T antigen and adnovims ElB oncoproteins 
(Lane et al. 1979; Linzer et al. 1979; Samow et al. 1982). The tumor suppressor p53 
protein has been called the 'guardian of the genome' and acts in response to a variety 
of cellular stresses to mediate antiproliferative effects (Lane 1992; Levine 1997). The 
p53 protein could be activated by D N A damage, hypoxia, nucleotide depletion and 
aberrant oncogene expression to promote cell cycle arrest, senescence, apoptosis and 
to protect cells from uncontrolled proliferation and neoplastic transformation (Fig. 
U ) . p53 is the most frequently mutated gene in human cancers ranging from 
20-50%. This implies that p53 plays a critical role in the development of human 
cancers (Greemblatt et al. 1994). 
The human p53 tumor suppressor gene spans a region of 20 kb with 11 exons and 10 
introns and is located in chromosome band 17pl3.1 (vanTuninen et al. 1988). The 
gene translates for a protein product with 53 kDa in size. The p53 protein is a D N A 
binding protein with transcriptional regulatory activities. Its primary protein structure 
ean be subdivided into four ftinctional domains. They are the acidic amino-terminal 
domain containing the activation domain (amino acid residues 1-42), the 
hydrophobic central core containing sequence-specific DNA-binding domain (amino 
acids 102-292), the tetramerization domain (amino acid residue 324-355), and the 
multifiinctional highly charged basic carboxy-terminal domain (amino acid residue 
363-393) (Fig. 1.2). 
The N-terminal of the protein consists of a transcription activation domain that 
interacts with many transcription factors such as TATA-associated factors TAF„70 
and TAF„31, which are both subunits of TFIID (Lu and Levine 1995; Thut et al. 
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1995) and TATA box-binding protein (TBP). The binding of M D M 2 to the 
N-terminal region inhibits p53 transactivation and leads to degradation through 
ubiquitination pathway. The core sequence specific'DNA binding domain of p53 
binds to four repeats of a consensus D N A sequence、5PuPuPuC(A/T)-3、，and this 
sequence is repeated in two pairs, each arranged as inverted repeats as ->•+《， 
where 今 is the sequence given above. The oligomerization domain is required for 
the formation oftetramer in order to bind D N A . The activity of p53 is controlled by 
the C-terminal domain. Phosphorylation at the C-terminus is necessary for efficient 
sequence-specific DNA-binding by p53 (Hupp T R et al. 1995). 
1.1.2 Regulation of p53 stability and activity 
The half-life of p53 is short in normal cells (20-30 minutes) due to M D M 2 mediated 
proteolysis through ubiquintination. However, in response to a variety of genotoxic 
stresses (DNA damaging agents, U V damage, nucleotide depletion, hypoxia or 
hypoglycemia) or inappropriate proliferative signals (c-Myc, E2F-1, El A or Ras), the 
p53 protein is stabilized and the protein level increases to exert its tumor suppressing 
functions (Fig. 1.1). 
Stabilization of p53 protein is attained by posttranslational modification. Ataxia 
telangiectasia (ATM) protein phosphorylates serine 15, stabilizes p53 and induces 
p53 target genes in response to 丫-irradiation (Kastan et al. 1992), A T M also activates 
Chk2, a kinase that phosphorylates p53 directly within the M D M 2 binding domain, 
reducing its binding to M D M 2 (Chehab et al. 2000; Hirao et al. 2000; Shieh et al. 
2000) ATM-Rad3 related protein (ATR) has also been shown to regulate 
phosphorylation of serine 15 of p53 in response to D N A damage (Tibbetts et al. 
1999). D N A - P K kinase has shown to activate p53 through phosphorylation at serine 
15 and 37 (Lees-Miller et al. 1992). 
3 
Hypoxia induced factor 1 alpha (HIFla) may mediate the stabilization of p53 in 
response to hypoxic condition (An et al. 1998). p53 could also be stabilized by a 
protein derived from the alternative reading frame dkived from INK4a (pl9ARF) 
which is required for the stabilization of p53 by the viral and cellular oncogenes 
(Quelle et al. 1995; Stott et al. 1998), such as El A, c-Myc, E2F-1 and Ras (Zindy et 
al. 1998; de Stanchina et al. 1998; Bates et al. 1998; Palmero et al. 1998) to induce 
cell cycle arrest. 
The D N A binding activity of p53 is also affected by the posttranslational 
modification at the C-terminal. Dephosphorylation of serine 376 of p53 by A T M 
creates a consensus binding site to 14-3-3g, which increases the ability of p53 to bind 
D N A (Waterman et al. 1998). Acetylation of the C-terminal lysine residues 320 and 
382 after D N A damage by p300/CBP and PCAF is shown to activate p53 (Gu and 
Roeder 1997; Sakaguchi et al. 1998). 
1.1.3 p53 and cell cycle arrest 
As mentioned above, p53 is activated during various cellular stresses. In response to 
D N A damage, cells either undergo apoptosis (Clarke et al. 1993; Lowe et al. 1993) or 
G1 cell cycle arrest (Kastan et al. 1991) by transactivation or transrepression of 
downstream genes. The G1 arrest in response to D N A damage is mediated through 
p53-induced expression of cyclin-dependent kinase inhibitor, p2lWAFi/ciPi (El-Deiry 
et al. 1993). p21 binds to a number of cyclin and cdk complexes: cyclin Dl-cdk4, 
cydin E-cdk2, cyclin A-cdk2 and cyclin A-cdc2 that inhibits the kinase activity and 
block the cell cycle progression. It also binds to P C N A and blocks its role as a D N A 
polymerase processivity factor in D N A replication. p53 may also be involved in G2 
arrest through induction ofGADD45 (Zhan et al. 1998), p21 (Bunz et al. 1998) and 
14-3-3(7 (Hermeking et al. 1997). 
1.1.4 p53 and apoptosis 
4 
There are at least two pathways to induce apoptosis in cells: intrinsic and extrinsic 
pathways. There are evidences showing that p53-mediated apoptosis after D N A 
» 
damage is involved in both pathways. 
p53 could regulate the expression of several members in the bcl-2 family through 
transcriptional regulation. The members in Bcl-2 family are divided into pro- and 
anti-apoptotic members such as the anti-apoptotic members, Bcl-2, BC1-XL, BC1-W 
and CED-9 and the pro-apoptotic members, Bax, Bad and Bid. p53 could 
transactivate Bax (Miyashita et ai. 1994) and Bid (Sax et al. 2002) and repress Bcl-2 
(Miyashita et al. 1994). The overall effect is to increase the ratio of pro- to 
anti-apoptotic Bcl-2 proteins, thereby favoring the release of cytochrome c from the 
mitochondria, caspase activation and apoptosis. p53 could also transactivate 
apoptosis protease activating factor-1 (Apaf-1) (Kannan et al. 2001; Moroni et al. 
2001; Robles et al. 2001) which forms the apoptosome with the activated caspase-9 
and initiates the caspase cascade. p53 could also upregulate caspase-6 expression 
which is considered as an effector caspase (MacLachlan et al. 2002). It appears that 
p53 would not induce apoptosis but potentiate cell death in the presence of released 
cytochrome c (Juin et al. 2002). 
The extrinsic pathway is also regulated by p53. The Fas/CD95/Apol (Owen-Schaub 
et al. 1995; Muller et al. 1998) an D R 5 (Wu et al. 1997) death receptor loci and the 
gene encoding for Fas ligand, TNFSF6 (Maecker et al. 2000) could be induced by 
p53. Fas/CD95/Apol belongs to the tumor necrosis factor (TNF) receptor 
superfamily. Binding of the Fas ligand will induce receptor trimerization and 
recruitment of the Fas-associated death domain (FADD) protein, which contains a 
death effector domain (DED), the initiator caspase 8 to form a complex called 
death-inducing signaling complex (DISC) and initiates caspase cascade and 
subsequent initiation of apoptosis. The D R 5 is a pro-apoptotic member of the 
5 
TNF-related apoptosis-inducing ligand (TRAIL) receptors which activates the 
caspase cascade in similar fashion. 
In addition to the ability of p53 to transactivate genes related to the apoptotic 
pathway, it could also induce genes targeting at the survival signaling. PTEN, a 
negative regulator of the PI3 kinase pathway (Stambolic et al. 2001). Prosurvival 
cytokines, such as growth factor, lead to the activation of the PI3 kinase production 
of phosphotidyl inositol-3,4-P2 and -3,4,5-P3 and activation of downstream effector 
kinase, Akt/PKB. Akt phosphorylates effector molecules and promotes cell survival. 
P T E N is a phosphatase that attenuates PI3 kinase signals. 
Beside its ability to induce cell cycle arrest and apoptosis, p53 could also regulate 
cellular senescence and D N A repair. So what are the factors that determine the effect 
of the p53 Mictions? Studies suggest that this is dependent on cell type or tissue of 
origin, strength or nature of the p5 3-activating stimulus, the presence of survival 
factors and the overexpression of oncogenes (Evan and Littlewood 1998). 
6 
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Fig 1 1 A variety of stimuli lead to the activation and stabilization of p53. D N A 
damaging agents and U V irradiation stabilize p53 through phosphorylation of p53 at 
its N-terminal and activate its D N A binding through dephosphorylation and 
acetylation of its C-terminal region. Hypoxia and hypoglycemia stabilize p53 
through both phophorylation dependent and independent mechanisms. Inappropriate 
oncogene stimulation leads to p53 stabilization through pl9ARF pathway. Disruption 
of m d m 2 and p53 interactions is critical for the stabilization of p53. Stabilized and 
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Fig 1 2 Functional domains of p53 and the post translational modifications which 
affect the stability and activity of p53. The four functional domains are the 
N-terminal transactivation domain (TA), central D N A binding domain, 
tetramerization domain and the C-terminal regulatory domain (CTD). Proline rich 
domain, PxxP (proline X X proline) is located between residues 60-90 where X 
stands for any amino acid residue, (adopted from Bums and El-Deiry 1999) 
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1.2 Mutation in p53 gene 
p53 is the most frequently mutated gene in human cancer. It is mutated in 50% of all 
tumors (Beroud et al. 1998; Hollstein et al. 1998; Haihaut et al. 2000). The mutation 
rate however is cancer type specific. The gene is mutated in more than 90% of head 
and neck squamous cell carcinomas (Kropveld et al. 1999) but the incidence is very 
low in hematological malignancies (Preudhomme et al. 1997). Over 85% of the p53 
mutations are missense mutation with a single amino acid substitution. The majority 
of point mutation occurs at the central D N A binding domain at “hot-spot’，codons 
175，248 and 273 etc (Levine 1997) (Fig. 1.3). The point mutation can be classified 
into two types: (a) amino acids for the direct DNA-binding (such as p53-R248W and 
P53-R273H); (b) those that will change the p53 conformation (such as p53-V143A 
and P53-R175H) (Cho et al. 1994; Wong et al. 1999). The mutation in the p53 gene is 
manifested with increased malignancy and tumorigenecity through dominant 
negative effect, transactivation-dependent tumor p r o m o t i o n a n d protein-protein 
interaction. 
1.2.1 Loss of function through dominant negative effect 
Mutation at the central D N A binding domain of the p53 gene would disrupt its ability 
to bind D N A and carry out its tumor suppression effect by transactivation. The loss 
of wild-type p53 Actions would impair the response of cells to genotoxic stresses. 
This alteration contributes to genomic instability and thus tumorigenesis. The 
mutation of p53 gene is dominant over the wild-type p53. p53 fo画 tetramer 
through the o l i g o m e r i z a t i o n domain and binds specific D N A sequence. A mutant p53 
protein can truncate a Actional tetramer and is therefore able to override the 
ftmction of the other three wild-type p53 proteins. Different p53 mutants show 
different degrees of dominance over wild-type p53 (Brachmann et al. 19%; Frebourg 
et al. 1994). 
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1.2.2 Gain-of-function through transactivation by mutant p53 
Although the loss of wild-type p53 function is sufficient to promote tumor 
progression, evidence has shown that mutant p53 gains new functions conferring 
increased resistance against drug-induced apoptosis, growth or survival (Dittmer et al. 
1993; van Oijen et al. 2000). The gain-of-function effects of mutant p53 are mediated 
by either direct or indirect transactivation of genes, including M D R l , EGFR, P C N A , 
VEGF, IL-6, bFGF, BAG-1 and c-myc (Table 1.1). Therefore, certain mutant p53 can 
exert mitogenic functions by upregulation of growth factor or growth factor receptor 
(p53-V143A, p53-R175H, p53-R248W, p53-R273H and p53-D281G) 
(Ludes-Meyers et al. 1996; Lanyi et al. 1998) and bFGF (Ueba et al., 1993), 
insulin-like growth factor I receptor (p53-V143A, p53-R248W and p53-R273H) 
(Werner et al. 1996) and interleukin 6 (p53-A135V) (Margulies et al. 1993); promote 
neoangiogenesis by induction of V E G F (p53-R175H) (Kieser et al. 1994) and exert 
tumor-promoting function by increasing the expressions of c-myc (p53-V143A, 
p53-R175H, p53-R248W, p53-R273H and p53-D281G) (Frazier et al. 1998) and Fos 
(p53-R175H, p53-R248W and p53-R273H) (Kawamura et al. 1996). In addition, 
mutant p53 could also induce resistance to various cancer therapies for example by 
induction of MDR-1 gene (p53-V143A, p53-R175H, p53-R248W, p53-R273H and 
p53-D281G) (Dittmer et al. 1993; Chen et al. 1994; Frazier et al. 1998; Lanyi et al. 
1998). 
1.2.3 Mutation in p53 and resistance to cancer therapy 
Drug resistance is one of the major obstacles in cancer therapy. The presence of 
mutant p53 was found to predict worse prognosis and reduced response to therapy in 
many tumors. For instance, p53-V143A made A2780 ovarian carcinoma cell line 
more resistant to irradiation, cisplatin, doxorubicin and cytarabin (Vasey et al. 1996); 
p53-R175H reduced the rate of ecoposide-induced apoptosis in p53-null H1299 cells 
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whereas p53-R273H induced a higher resistance to cisplatin (Blandino et al. 1999), 
etc. The resistance is made possible through the loss of wild-type p53 functions by 
dominant negative effect. Two p53 homologues, p63 and p73, are involved in p53 
transactivation of target genes and cooperate with p53 to induce apoptosis under 
genotoxic agents. Mutant p53 dimerizes with p63 and p73 in a dominant negative 
manner and impairs p53 target genes activation, like p21, bax, etc (Soussi 2003). 
Mutant p53 could also induce resistance to cancer therapy through 
"gain-of-function" transactivation of different target genes like M D R l as mentioned 
before. Other target genes include activation of dUTPase gene leading to resistance 
to 5-fluorouracil (Pugacheva et al. 2002), repression of Fas/CD95/Apol gene 
expression that may contribute to cell killing by D N A damage agents in cells lacking 
wild-type p53 (Zalcenstein et al. 2003), etc. Therefore, it is believed that mutant p53 
is associated with chemo- or radio-resistance in cancer therapy. The responses of 
tumor cells to drug or radiation-induced toxicity are drug- and mutant- specific. 
Hence, characterization of gain-of-functions of mutant p53 would be important for 
prognosis in chemotherapy or radiotherapy. And finally, it is also helpful in designing 
a successful cancer therapy regime. 
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Fig. 1.3. p53 gene structure and mutations. (A) The bars represent the percentage of 
mutations found in tumors that were primarily investigated for core domain 
mutations. (B) The p53 gene consists of 11 exons encoding a protein that comprises a 
transactivation domain, a core domain/ sequence-specific DNA-binding domain, and 
COOH-terminal domain with tetramerization domain and nonspecific DNA-binding 
domain. Boxes, conserved domains. (Adopted from van Oijen and Slootweg 2000). 
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Functions gained References 
Promoter transactivation 
M D R I Ghin et al. 1992 
E G F R Deb et al. 1994 
c-myc Frazier et al. 1998 
BAG-1 Yang et al. 1999 
Pos Preuss et al. 2000 
P C N A Kawamura et al. 1996; Lanyi et al. 
1998; Deb etal. 1992 
V E G F Kieser et al. 1994 
IGFI-R Werner et al. 1996 
bFGF Ueba et al. 1994 
IL-6 Margulies et al. 1993 
Increased tumorigenecity Dittmer et al. 1993 ； Layi etal. 1998 
Increased growth in soft agar Dittmer et al. 1993 
Altered protein-protein interactions 
M B P I Gallagher et al. 1999 
53BP-1 and -2 Iwabuchi et al. 1994 
p42 and p38 Chen etal. 1994 
M d m 2 Peng et al. 2001 ； Brown et al. 2001 
Increased metastatic potential and tissue invasiveness Hsiao et al. 1994; Pohl et al. 1988; 
Liu et al. 2000 
Increased resistance to chemotherapy Blandino et al. 1999; Li et al. 1998; 
Wang et al. 1998a,b 
Increased resistance to y-IR Li et al. 1998 
Accelerated chemical carcinogenesis Wang et al. 1998a,b 
Stimulate IR-induced homologous recombination Saintigny et al. 1999 
Disruption of spindle checkpoint Gualberto et al. 1998 
Enhanced Topo I catalytic function Albor et al. 1998 
Table 1.1. Gain-of-function properties of mutant p53 (modified from van Oijen et al. 
2000 and Cadwell et al. 2001). 
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1.3 Objective of the study 
To study the functional role of mutant p53, a p53-null cell line, human osteosarcoma 
» 
Saos-2 cells, was employed (Dittmer et al. 1993). The advantage of using this model 
in the mutant p53 gain-of-function study is that the complications from the dominant 
negative phenotype of mutant p53 proteins could be avoided. Any acquired 
phenotype after transformation of cells with the mutant would be accounted for the 
gain-of-function effect of the mutant p53. Two p53 mutants, a conformation mutant 
with point mutation at codon 143 valine to alanine (p53-V143A) and a D N A binding 
mutant with point mutation at codon 273 arginine to histidine (p53-R273H), were 
transfected into Saos-2 cells. The control cells were transfected with vector only. 
In the present study, the role of mutant p53 in the response of human osteosarcoma 
Saso-2 cells to cancer chemotherapy and immunotherapy will be examined. There 
are various kinds of cancer therapy, e.g. chemotherapy and immunotherapy. 
Immunotherapy refers to the use of cytokines as therapeutic agents or in adjuvant 
agent, e.g. interferon. However, resistance to such therapy occurs and the underlying 
mechanism is not clear. The role of mutant p53 in interferon sensitivity of Saos-2 
cells and its regulation of the JAK/STAT patheway will be discussed in Chapter 2. 
Mutation in p53 has been correlated with multidrug resistance, possibly through the 
gain-of-function effect of the mutant p53 as discussed before. However, the 
mechanism by which mutant p53 induces multidrug resistance is yet to be 
characterized. In Chapter 3, the possibility of mutant p53-mediated multidrug 
resistance through JAK/STAT pathway will be discussed. 
14 
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Chapter 2 Mutant p53 induced interferon resistance and 
its regulation of the Jak/Stat pathway 
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2.1 Introduction 
There are different strategies in cancer treatment', for instance, chemotherapy, 
radiotherapy, immunotherapy, etc. Immunotherapy refers to the use of cytokines to 
directly or indirectly induce regression of tumors through antiproliferative and 
proapoptotic effects or to potentiate the killing effect of other therapeutic agents. 
Interferons (IFNs) are antiviral cytokines, which are induced during viral infection, 
and inhibit the replication of other viruses (Issacs et al. 1957). IFNs are also able to 
block proliferation of some cancer cells and are used as therapeutic agents in cancer 
treatment. IFNs bind to their cognate receptors and activate Janus kinases (JAKs) and 
signal transducers and activators of transcription (STATs) in the JAK/STAT pathway 
to regulate gene transcription and finally cellular responses. 
However, the responses to IFNs treatment vary in different kinds of malignancies and 
also even in the same kind of malignancy in some cases. It is proposed that resistance 
to IFNs may be correlated with alteration in the JAK/STAT components (Wong et al. 
1997; Pansky et al. 2000). Therefore, it is interesting to determine if mutant p53 
would play a role in such resistance by the 'gain of function' effect. 
2.1.1 IFN classification and biological activities 
IFNs are classified into two classes, type I and type II IFNs. Type I IFNs all bind to 
same type of receptor, type I IFN receptor, which includes IFN-alpha, IFN-beta, 
IFN-omega and IFN-tao. IFN-gamma is the only member in the type II IFN and 
binds to the distinct type II receptor (Pfeffer et al. 1998). IFN-alpha, a type I IFN, 
and IFN-gamma, a type II IFN are the focus of this study. 
Type I IFNs are produced in almost all cell types in response to viral infection, 
double-stranded R N A , polypeptides and cytokines (Sreevalsan 1995). The type II 
IFN-gamma is produced in T cells and natural killer (NK) cells following a number 
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of immunological stimuli, including T cell-specific antigens, staphylococcal 
enterotoxin A, etc (Sreevalsan 1995; Pestka 1997). Unlike type I IFNs, it is not 
directly induced in cells following viral infection. ‘ 
The IFNs possess a variety of biological activities including antiviral activity, impact 
cellular metabolism and differentiation, and possess antitumor activity. The 
antitumor effects attribute to a combination of direct antiproliferative and indirect 
immunomodulatory effects. In this study, we focus on the direct antiproliferative 
properties on cells. 
2.1.2 IFN signaling 
Cells with IFN receptor subunits are primed to respond to signaling events driven by 
the dimerization of receptor subunits upon ligand binding, leading to the 
phosphorylation at the cytoplasmic domain of the receptor, Janus-activated kinases 
(Jaks), signal transducers and activators of transcription (Stats), dimerization of Stat 
proteins and subsequently gene transcription. 
In IFN-alpha signaling, Statl and Stat2 are preassociated with IFNAR-2 subuint, 
Tyk2 is with IFNAR-1 (Colamonici et al. 1994a;b) and Jakl with IFNAR-2 (Gauzzi 
et al. 1996). Binding of IFN-alpha to IFNAR-2 induces dimerization of the receptor 
subunits and brings the Jak kinases together, allowing cross-phosphorylation to occur. 
Tyk2 is phosphorylated by Jakl, which in turn cross-phosphorylates Jakl to increase 
its kinase activity. The tyrosine residue 466 on IFNAR-1 is phosphorylated (Krishnan 
et al. 1996) creating a docking site for latent Stat2 through an interaction of the 
phosphotyrosine residue on IFNAR-1 and the Src homology 2 (SH2) domain on 
Stat2. Stat2 then becomes phosphorylated, at tyrosine residue 690 (Leung et al. 1995; 
Nadeau et al. 1999), providing a docking site for recruitment of Statl to IFNAR-1 
which is also phosphorylated, at tyrosine residue 701, and activated. Activated Statl 
and Stat2 form a heterodimer and are released from the receptor to interact with the 
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IRF-1 family member p48 or IFN-stimulated gene factor 3 gamma (ISGF3 gamma) to 
form a complex called IFN-stimulated gene factor 3 (ISGF3). The heterodimers are 
translocated into the nucleus and initiate transcription of IFN-stimulated genes (ISGs) 
through binding to promoters with an IFN-stimulated response element (ISRE) (Fig. 
2.1.1) (John et al. 1991; Bluyssen et al. 1995). 
In IFN-gamma signaling, Jakl preassociates with IFN-gamma receptor subunit 
IFNGRl and Jak2 with IFNGR2. Signal transduction is initiated when a 
homodimeric IFN-gamma molecule binds to two IFNGRl subunits, leading to 
formation of a complex to which two IFNGR2 subunits subsequently bind. Within 
the ligand-assembled receptor complex, the inactive subunit-associated kinases are 
brought into close juxtaposition with one another and are activated by auto- and 
transphosphorylation. Once activated, the receptor-associated Jaks phosphorylate a 
tyrosine-containing five-residue sequence ( 4 4 0 Y D K P H 4 4 4 ) near the C terminus of 
IFNGRl forming a docking site recognized by the SH2 domain of Statl (Greenlund 
et al. 1994; Igarashi et al. 1994; Greenlund et al. 1995). Two Statl proteins bind to 
the paired docking sites on the activated receptor complex and are phosphorylated by 
the receptor-associated activated Jaks at specific tyrosine residue 701 (Schindler et al. 
1992; Shuai et al. 1993). Two phosphorylated Statl proteins then dissociate from the 
IFNGRl subunits and form reciprocal homodimer which has also been 
phosphorylated at serine during the activation process. The homodimer is then 
translocated into nucleus and regulates transcription of genes with promoter 
sequence known as gamma-interferon activated sites (GAS) (Fig. 2.1.1) (Durbin et al. 
1996； Meraz et al. 1996; Neubauer et al. 1998; Rodig et al. 1998; Paraganas et al. 
1999) 
2.1.3 IFN direct antitumor effect: cell cycle arrest and apoptosis 
IFNs can exert direct antitumor effect on tumor cells by inducing cell cycle arrest and 
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apoptosis through gene regulation. Although the mechanisms for their 
antiproliferative effect remain unclear, the downregulation of the proto-oncogene 
c-myc and the induction of the enzyme 2'5'-oligbadenylate synthetase may be 
involved (Kimci 1987; Bishoffet al. 1985). 
IFN-alpha has been shown to induce G1 arrest in hematopoietic cells. This arrest is 
mediated by regulation of a number of genes involved in cell cycle progression, 
including inhibition of c-myc expression (Einat et al. 1985), inhibition of 
phosphorylation of retinoblastoma protein (Rb) (Thomas et al. 1991; Resnitsky et al. 
1992), downregulation of E2F activity (Melanmed et al. 1993), induction of 
cyclin-dependent kinase inhibitor (CDK inhibitor) p2lWAF"ciPi, ^ ^^ ^nd 
(Hobeika et al. 1997; Subramaniam et al. 1997; Arora et al. 1998). 
IFN-alpha has demonstrated ability in inducing apoptosis in cell lines by a 
mechanism independent on its antiproliferative effect (Jewell et al. 1996; Sangfelt et 
al. 1997). IFN-alpha was shown to be able to induce apoptosis in hematopoietic cell 
lines through a Bcl-2, Bax and p53-independent pathway (Sangfelt et al. 1997) and 
also in myeloma cells through a Fas/Fas ligand-independent pathway. But IFN-alpha 
could upregulate IL-6, IL-6R, interferon regulator factor 1 (IRFl) and IRF2 in these 
cells which maybe involve in IFN-alpha induced apoptosis (Otsuki et al. 1998). 
IFN-gamma could also induce cell cycle arrest and apoptosis in various cell lines. 
IFN-gamma mediates GO/Gl arrest in melanoma cell lines without enhancement of 
C D K inhibitors, p21 and p27 but it may correlate with downregulation of cyclin E 
and cyclin A and inhibition of their associated kinase activities (Kortylewski et al. 
2004). IFN-gamma induces expression of IRF-1 that has been proposed to regulate 
cell cycle arrest in primary hepatocytes (Kano et al. 1999). 
The ability of IFN-gamma to induce apoptosis also varies in different cell lines. 
IFN-gamma induction of IRF-1 was shown to be an essential mediator of 
1 9 
IFN-gamma induced apoptosis in hepatocytes (Kano et al. 1999). IFN-gamma 
increases cellular apoptosis in gastric cancer cells by upregulating of Bak, which is a 
pro-apoptotic member in the Bcl-2 family involved iri cytochrome c release (Wang et 
al. 2001; Degenhardt et al. 2002) and downregulation of Bcl-2 and Bcl-Xs protein 
levels (Shyu et al. 2000). The sensitivity of colon adenocarcinoma cell line to 
apoptosis is increased by IFN-gamma through induction of CD95 and TNFRl, 
interleukin-1 p-converting enzyme (Ice) family members, Ice (caspase-1), Cpp32 
(caspase-3), ICErd-H, Mch-3, Mch-4, Mch-5 which are the alternative splicing 
variants of the ICE/CED-3 family (Ossina et al. 1997; Lutz et al. 1998; Iwase et al. 
1999; Ruiz-Ruiz et al. 2000). Moreover, IFN-gamma sensitizes neuroblastoma cells 
for apoptosis by upregulating caspase-8 expression in the extrinsic apoptotic pathway 
(Fulda et al. 2002). 
Although there are quite a substantial evidence showing that IFNs are able to 
regulate cell cycle arrest and apoptosis, the mechanisms are not well defined as there 
are many IFN regulated genes, for example, there are about 100 
IFN-gamma-regulated genes identified so far (Kerr et al. 1991; Boehm et al. 1997; 
Der et al. 1998). Moreover, cellular responses to interferon seem to be cell type- and 
stimulus-specific. 
2.1.4 IFN in immunotherapy 
IFNs provide important treatment of a number of solid tumors and hematological 
malignancies. These include melanoma, renal cell carcinoma (RCC), hairy cell 
leukemia and chronic myelogenous leukemia (CML). IFN could also be used in 
combination therapy. For instance, combination of IFN-alpha, IL-2 and 5-FU have 
been used in treatment of metastatic RCC; combination of IFN-alpha and cytarabine 
in treatment of C M L , etc (Jonasch et al. 2001). IFN-alpha is more commonly used in 
cancer therapy. In addition to the above malignancies, it is also used in the treatment 
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of follicular lymphoma, Kaposi's sarcoma, etc. On the other hand, clinical trials of 
IFN-gamma for treatment of many different solid and hematological tumors have 
been disappointing. One of the few cancers that have been shown to regress in 
response to IFN-gamma therapy is C M L (Kurzrock et al. 1987). 
2.1.5 Resistance to IFN therapy 
Resistance to IFN therapy could be observed in various tumors. Efforts have been 
made in understanding such resistance and different mechanisms have been proposed. 
Resistance to IFN-alpha appears to be associated with failure to induce IRFl and 
IRF7 and deregulation of the apoptotic signals of hypermetylation of X-linked 
inhibitor of apoptosis-associated factor 1 (HSXIAPFl), TNF receptor-associated 
death domain (TRADD), Bad and BNIP3. XIAP-associated factor 1 (XAFl) has 
been identified to negatively regulate the caspase-inhibiting activity of XIAP and 
therefore potentiates cells for apoptosis. Recruitment of death domain containing 
adaptors such as T R A D D leads to activation of the death receptor pathway that 
induces cell death. Bad is a proapoptotic member of Bcl-2 family that binds BCI-XL-
BNIP3 is a member of BH3-only subfamily of Bcl-2 family proteins that 
heterodimerizes and antagonizes the activity of prosurvival proteins Bcl-2 and 
BC1-XL. Deregulation of these signals may make cells resistant to IFN induced cell 
death. Additionally, resistance is also attributed to cell cycle progression promoted by 
upregulation of CDC25A and CDC42. A critical role of NF-KappaB in promoting 
cell survival in IFN-alpha-resistant cells is indicated by the upregulation of RELB 
and LIB (Leukotriene B) (Tracey et al. 2004). Resistance to IFN-gamma is 
associated with IRF-1 and p21 in ovarian cancer cell lines. Resistant cells showed 
rapid increase in p21 and IRF-1 but this increase was not sustained (Burke et al. 
1999). Overexpression of Jak-binding protein (JAB) or suppressors of cytokine 
signaling (SOCS) also confers IFN resistance. JAB/SOCS is a negative regulator of 
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IFN response (Sakamoto et al. 2000). There are also plenty of evidences showing 
that the IFN resistance is due to alteration in the components of the Jak/Stat pathway. 
Resistant cells usually show a defect in Jak/Stat pathway (Pansky et al. 2000). 
Chronic myeloid leukemia and cutaneous T-cell lymphoma resistant to IFN-alpha are 
lack in Statl expression (Sun et al. 1998; Landolfo et al. 2000). IFN-alpha resistance 
in renal carcinoma cells is associated with defective induction of Statl (Brinckmann 
et al. 2002). Some interferon-resistant human melanoma cells are found to be 
deficient in ISGF3 components, Statl, Stat2 and ISGF3gamma (Wong et al. 1997). 
Lack of ISGF3 gamma expression impairs IFN-alpha signaling in transitional cell 
carcinoma (Matin et al. 2001). 
Although IFNs have been used in treatment of cancer for decades, individual 
response to IFN treatment is unpredictable and mechanisms of resistance remain 
unclear (Tracey et al. 2002). Mutations of p53 have been found in hematological 
malignant diseases but the frequency is much lower than that in solid tumors. These 
mutations occur especially as hematopoietic abnormalities become more malignant 
such as going from the chronic phase to the blast crisis of chronic myeloid leukemia 
(Krug et al. 2002). 
In this chapter, the role of mutant p53 in IFN sensitivity of human osteosarcoma 
Saos-2 cells transfected with control vector only and mutant p53-V143A and 
p53-R273H will be discussed. Furthermore, the levels of IFN associated apoptosis 
and cell cycle will also be studied. Mechanisms by which mutant p53 proteins gain 
resistance to IFN may involve its regulation of the Jak/Stat pathway components. 
Furthermore, the role of these signaling molecules in IFN signaling and sensitivity 
will be studied by inhibitor experiments. 
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Fig. 2.1.1 IFN-alpha and IFN-gamma signaling pathway. For IFN-alpha, there are 
two receptor subunits, IFNAR-1 and IFNAR-2, which bind the Janus-activated 
kinase (Jak) molecules Tyk2 and Jakl, respectively. For IFN-gamma, there are two 
receptor subunits, IFNGR-1 and IFNGR-2, which associate with Jakl and Jak2, 
respectively. Upon binding of IFN to its receptor, the receptor undergoes 
oligomerization, with transphosphorylation of Jaks followed by phosphorylation of 
the cytoplasmic tails of the receptor molecules. This provides a docking site for the 
signal transducers and activators of transcription (Stats), which are then 
phosphorylated by the Jaks. The phosphorylated Stat dimmers are released from the 
receptor molecules and translocate to the nucleus, where they activate transcription 
of IFN-stimulated genes (ISGs). In the case of IFN-alpha, ISGs can be identified by 
the presence of an IFN-stimulated response element (ISRE) in their promoter regions. 
Enhancers of IFN-gamma-inducible genes contain a unique element called the 
IFN-gamma activation site (GAS) (Jonasch et al. 2001). 
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2.2 Materials and methods 
2.2.1 Cell lines 
The human osteosarcoma Saos-2 cells transfected with pcDNA-Bam-Neo vector 
alone (control), or vector carrying mutant p53-V143A (valine to alanine) or 
p53-R273H (arginine to glycine) was gifted from Dr. Levine, Princeton University, 
U S A (Dittmer et. al., 1993). Cells were maintained in Dulbecco modified Eagle's 
medium ( D M E M ) (Life Technologies, Inc., USA) with 10% fetal bovine serum 
(Invitrogen Life Technologies, HK), 2 m M L-glutamate (Life Technologies, Inc., 
U S A ) and 20 ug/ml of G418 (Calbiochem, Germany) in 3 7� C humidified 10% CO2 
incubator. 
2.2.2 Drugs and antibodies 
AG490, JAK inhibitor I (Jakil) (Calbiochem, Germany), interferon-alpha, 
interferon-gamma (Biosource Int. USA) were employed. AG490 and Jak inhibitor I, 
were dissolved in dimethyl sulfoxide (DMSO) (Sigma, USA). Interferon-alpha and 
interferon-gamma were reconstituted in phosphate buffered saline with 0.1% bovine 
serum albumin sterilized by filtering. Vincristine and taxol were dissolved in water 
and sterilized by filtering. 
The primary antibodies used in the Western Blot analysis included anti-JAKl, JAK2, 
JAK3, TYK2, STATl, STAT2, STAT3, STAT4, STAT5, STAT6, ISGF3y (BD 
Transduction Laboratories), p-JAK2, p-STATl, p-STAT3, p-STAT5, Caspase 3, 
Caspase 8, Caspase 9 (Santa Cruz Biotechnology Inc., USA), etc. 
2.2.3 Cell Proliferation assay- MTT assay 
1.8 X 104 cells were seeded in each well of a 96-well plate for 2 days. Medium with 
different concentrations of drugs was added and incubate for further 5 days. Cells 
were then incubated with 50 ul of 0.1 mg/ml 
3.(4^5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) (Sigma, 
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U S A ) in PBS for 3 hours. Yellow M T T dye was reduced by mitochondrial 
dehydrogenase to form purple formazan which was solubilized by 150 ul of dimethyl 
sulfoxide (DMSO). Absorbance was read at 570 n m using a microplate reader. 
2.2.4 Cell cycle analysis 
Cells after drug treatment were collected by trypsinization and washed once with 
PBS. The cells were then fixed in 1 ml 70% ethanol overnight. Cells were then 
centrifUged and washed once by PBS. Cells were resuspended in 0.5 ml lysis buffer 
containing 0.1% Triton X-100, 80 ug/ml ofRNase A (Sigma, USA) and 40 ug/ml of 
propium iodide (Sigma, USA) for 30 min at room temperature. Subdiploid D N A was 
measured by FACSort flow cytometer and analyzed by software WinMDI 2.5. 
2.2.5 DNA fragmentation assay 
4.5 to 8 X 10^ cells were seeded in a 6 0 m m dish for 3 days. After drug treatment, 
cells were washed by PBS and trypsinized. Cells were then collected and lysed in 
lysis buffer (5mM Tris-HCl, 100 m M EDTA, 1% SDS and proteinase K (Sigma) for 
1 hour at 45°C. Genomic D N A was extracted and proteins were removed by 
phenol/chloroform/isoamyl alcohol (25:24:1). D N A was precipitated in 70% ethanol 
at -20。C overnight and by centrifugation. R N A was removed by incubation in 
Tris-EDTA buffer at pH 8.0 with 0.4 ug/ml of RNase A (Sigma) at 3 7 � C for 2 h. 
Same amount of D N A was loaded and visualized on a 1.5% agarose gel with 5 ug/ml 
of ethidium bromide and run at 80V for 1 h. 
2.2.6 Western blot analysis 
Cells with or without treatment were washed 3X with chilled PBS containing I m M 
ortho-vanadate and then lysed with protein lysis buffer (2.1 ug/ml aprotinin, 0.5 
ug/ml leupeptin, 4.9 m M MgCli, 1 m M ortho-vanadate, 1% Triton X and 1 m M 
phenlymethanesulfonyl fluoride) and scraped by a cell lifter. Protein lysate was 
collected by centrifugation of 14000 rpm at 4。C for 7 min and 0.5ul of the 
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supernatant was taken for protein quantification by B C A Protein Assay Reagents 
(Pierce). Supernatant of the lysate was saved, added with equal volume of 2X SDS 
sample buffer and denatured by boiling for 10 min. 
25 ug of protein sample was resolved in SDS-PAGE minigel at 200 V for 24 to 45 
min. Proteins were then transferred onto an Immobilon-P mambrane (Millipore) 
soaked with E-blot transfer buffer at 15 V for 35 minutes. Membrane was blocked by 
5 % non-fat dry milk at 4。C overnight and then washed with PBS-T (IX PBS with 
0.1% Tween 20). The membrane was incubated with primary antibody at room 
temperature for 2 h and then probed with the corresponding secondary antibody 
conjugated with horseradish peroxidase in 1:10000 dilution (Zymed). After 
stringency washes, chemiluminescence signal was developed with the ECL Western 
Blotting Detecting Reagents (Amersham) and visualized in X-ray film (Kodak). 
2.2.7 Combined treatment of IFNs and Jak inhibitors in MTT assay, DNA 
fragmentation assay and Western blot analysis 
In the cell proliferation study and D N A fragmentaion assay, cells were under 
co-incubation of IFN and Jak inhibitors for five days to see the effect of continuous 
inhibition of Jaks on IFN sensitivity and IFN induced fragmentation in Saos-2 cells. 
The Jak/Stat pathway was found to be activated under the treatment of IFN within 15 
minutes. In the Western blot analysis, cells were pre-incubated with AG490 for 16 
hours to suppress the enzymatic activity of Jak and stimulated with IFN for 15 
minutes without the presence of inhibitor. 
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2.3 Results 
2.3.1 Mutant p53-V143A and p53-R273H induced IFN resistance: the role of 
IFN induced apoptosis and cell cycle arrest 
In order to determine if mutant p53 has a role in IFN resistance, M T T cell 
proliferation assay was employed. It is shown that cells transfected with mutant p53 
were more resistant to IFN-alpha and IFN-gamma (Fig. 2.3.1). Their I C 5 0 values are 
shown in Table 2.3.1. 
One common mechanism by which cells gain resistance to the IFN toxicity is 
through resistance to the IFN induced apoptosis. The IFN resistance with respect to 
IFN induced apoptosis was therefore studied by D N A fragmentation assay (Fig 2.3.2). 
Both IFN-alpha and IFN-gamma were able to induce D N A fragmentation in the 
control cells in a dose-dependent manner. The mutant p53-V143A and p53-R273H 
transfectants however showed less extent of D N A fragmentation upon IFN-alpha and 
-gamma treatment. This indicated that the resistance of mutant p53-V143A and 
p53-R273H transfectants to IFN-alpha and IFN-gamma may be through decreased 
sensitivity to IFN-alpha and IFN-gamma induced apoptosis. 
This notion was further confirmed by the cell cycle analysis. The sub-Gl peak 
represented the apoptotic cell population. IFN-alpha induced sub-Gl peak at 48 and 
72h of incubation more significantly in the control cells than in mutant p53-V143A 
and p53-R273H transfectants. Similarly, mutant p53 transfectants were more 
resistant to the IFN-gamma induced sub-Gl peak at 48 and 72h than the control cells. 
Moreover, IFN-alpha and IFN-gamma both induced G1 arrest after 16 h of treatment 
in the control cells, but the effect was less significant in the mutant p53-V143A and 
p53-R273H transfectants. It seemed that mutant p53-V143A and R273H make 
Saos-2 cells more resistant to IFN-alpha and IFN-gamma induced G1 arrest. 
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2.3.2 IFN induction of apoptosis: a p53-mdependent and caspase-dependent 
pathway 
IFN-alpha and IFN-gamma could induce apoptosis in Saos-2 cells that is a p53 null 
cell line. Therefore, the process of IFN induced apoptosis may be mediated through a 
p5 3-independent pathway. To understand the mechanism of IFN induced apoptosis, 
the levels of the pro and active form of caspases 3, 8 and 9 were studied. Caspase 3 is 
the effector caspase that is activated during apoptosis. It is therefore described as the 
'point of no return, in the apoptotic pathway. Caspase 8 is activated by signals from 
the extrinsic apoptotic pathway such as death receptor and caspase 9 is activated by 
signals from the intrinsic pathway inculding mitochondrial membrane potential 
disruption, cytochrome c release followed by the formation of apoptosome. The 
activation of caspases 8 and 9 could lead to cleavage of caspase 3 and apoptosis 
subsequently. 
Cleavage of caspase-3 could be detected in Saos-2 control cells treated with 500U/ml 
IFN-alpha for 48 and 72h in a time-dependent manner (Fig 2.3.5) and with 5ng/ml 
IFN-gamma most significantly at 72h. Such cleavage could hardly be seen in mutant 
p53 transfectants. 
There seemed to be a slight cleavage of caspase 8 in the control cells induced by 
IFN-alpha and IFN-gamma but not in mutant p53 transfectants. There is no sign of 
caspase 9 cleavage. 
The caspase cascade activation induced by IFN-alpha and IFN-gamma in Saos-2 
cells seemed to be quite similar. They both involve caspase 8 and caspase 3 
activation. Therefore, IFNs induced apoptosis in Saos-2 cells may be mediated 
through the activation of the death receptor pathway independent of wild type p53 
pathway in Saos-2 cells. 
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Fig 2.3.1 Sensitivity of Saos-2 cells to (A) IFN-alpha and (B) IFN-gamma. Cells 
were seeded for 2 days and incubated further with IFNs for 5 days. Cell viability was 
determined by M T T assay. Standard deviation was obtained from more than 3 
separate experiments. •: Saos-2 control cells; •: Saos-2 p53-V143A transfectant; 
A : Saos-2 p53-R273H transfectant. 
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Control cells p53-V143A p53-R273H 
IFN-alpha (U/ml) 100 >1000 ‘ 200 
IFN-gamma (ng/ml) 8.6 >20 >20 
Table 2.3.1 I C 5 0 values of Saos-2 cells to IFN-alpha and IFN-gamma. 
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Fig 2.3.2 IFN induced D N A fragmentation in Saos-2 cells. Cells were seeded for 3 
days to sub confluence. IFN was added and further incubated for 3 days. Cells were 
then harvested and subjected to D N A fragmentation assay. (A) IFN-alpha induced 
D N A fragmentation. Lane 1: control; lane 2: 500U/ml IFN-alpha; lane 3: lOOOU/ml 
IFN-alpha. (B) IFN-gamma induced D N A fragmentation. Lane 1: control; lane 2: 
5ng/ml IFN-gamma; lane 3: lOng/ml IFN-gamma. The experiments were repeated 
for three times and similar results were obtained. The one shown was the 
representative one. 
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Fig 2.3.3 Cell cycle and apoptosis in Saos-2 cells after IFN-alpha treatment as 
analyzed by flow cytometry. Sub confluent cells were treated with 500U/ml 
IFN-alpha for 16, 24, 48 and 72 h. Cells were fixed with 70% ethanol and stained 
with propidium iodide. Subdiploid D N A was measured by FACSort flow cytometer 
and analyzed by software WinMDI 2.5. Red area: control; Black line: treatment with 
IFN-alpha. •: sub-Gl; _: Gl;圖：S; _ : G2/M phases in cell cycle. The 
experiment was repeated once and similar result was obtained. The one shown was 
the representative one. 
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Fig. 2.3.4 Cell cycle and apoptosis in Saos-2 cells after IFN-gamma treatment as 
analyzed by flow cytometry. Sub confluent cells were treated with 5ng/ml 
IFN-garmna for 16, 24, 48 and 72 h. Cells were fixed with 70% ethanol and stained 
with propidium iodide. Subdiploid D N A was measured by FACSort flow cytometer 
and analyzed by software WinMDI 2.5. Red area: control; Black line: treatment with 
IFN-gamma. •: sub-Gl; _: Gl;圓：S; _ : G2/M phases in cell cycle. The 
experiment was repeated once and similar result was obtained. The one shown was 
the representative one. 
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Fig. 2.3.5 IFN-alpha and IFN-gamma induced caspase cascade activation. Sub 
confluent cells were treated with IFN for various times, proteins were lysed and 
resolved in SDS-PAGE gel. Proteins were transferred to membranes and probed with 
specific antibodies recognizing pro and active form of caspases. The intensity of the 
protein band was quantified by program Kodak Digital Science ID Scientific 
Imaging System. The numerical value next to the protein band is the relative 
expression of the specific protein which is calculated as the ratio between the protein 
band intensity for a specific condition in relation to that for the control cells under 
control condition. (A) Lane 1: control; lane 2, 3 and 4: treatment with 500U/ml 
IFN-alpha for 24，48 and 72 hours respectively. (B) Lane 1: control; lane 2, 3 and 4: 
treatment with lOng/ml IFN-gamma for 24, 48 and 72 hours respectively. 
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2.3.3 Mutant p53 regulation of Jak/Stat pathway 
IFN resistance has been correlated with alteration in the Jak/Stat signaling pathway. 
The possibility of mutant p53 regulation of the Jak/Stat pathway was studied by 
measuring the protein expressions of the signaling molecules in the Jak/Stat pathway 
using Western blot analysis. The expression level was expressed as band intensity 
analyzed by the program Kodak Digital Scientific ID Scientific Imaging System. The 
expressions of the Jak/Stat signaling molecules were shown in Fig. 2.3.6-7 and the 
profile was summarized in Table 2.3.2. 
There are four members in the Janus kinase family, Tyk2, Jakl, Jak2 and Jak3. It was 
observed that there was a downregulation of the Janus kinase (Jaks) in mutant p53 
transfectants: Tyk2 in both p53-V143A and p53-R273H, Jak2 in p53-R273H 
transfectants. For Stats, Stat2, 4 and 5 were found to be downregulated in both 
mutant p53 transfectants; Stat6 was upregulated only in p53-R273H transfectant and 
Statl was upregulated in p53-V143A transfectant. The expression of other Stat 
proteins were similar between Saos-2 control cells and mutant p53 transfectants. The 
expression of mutant p53 in Saos-2 cells was also shown. Since downregulation of 
Jaks (Tyk2 and Jak2) appears to correlate with the IFN resistance in Saos-2 cells. 
Two inhibitors targeting at the Janus kinases were employed to see if they might 
affect IFN sensitivity in Saos-2 cells. The inhibitors are AG490, a specific Jak2 
inhibitor, and Jak inhibitor I, inhibiting all four Janus kinases. The sensitivity of 
Saos-2 cells to AG490 and Jak inhibitor I was shown in Fig. 2.3.8. 
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Fig. 2.3.6 Basal protein expressions of Janus kinases (Jaks) and p53 in Saos-2 cells. 
Sub confluent cells were lysed for protein, resolved in SDS-PAGE gel and 
transferred to a membrane. The membrane was probed with specific antibody. 
Signals were visualized under an X-ray film using the E C L system. The band 
intensity was estimated by program Kodak Digital Science ID Scientific Imaging 
System. The relative protein expression levels in mutant p53 transfectants were 
calculated by: band intensity of a protein in mutant p53 transfectant / band intensity 
of that protein in control cells. Standard deviation was obtained from three or more 
separate set of experiments. • : Control cells;皿：p53-V143A transfectant;國： 
p53-R273H transfectant. p<0.05; **: p<0.005. 
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Fig. 2.3.7 Basal protein expressions of signal transducers and activators of 
transcription (Stats) and IFN-stimulated gene factor 3 gamma (ISGF3gamma) in 
Saos-2 cells. Sub confluent cells were lysed for protein, resolved in SDS-PAGE gel 
and transferred to a membrane. The membrane was probed with specific antibody. 
Signals were visualized under an X-ray film using the E C L system. The band 
intensity was estimated by program Kodak Digital Science ID Scientific Imaging 
System. The relative protein expression levels in mutant p53 transfectants were 
calculated by: band intensity of a protein in mutant p53 transfectant / band intensity 
of that protein in control cells. Standard deviation was obtained from three or more 
separate set of experiments•口： Control cells;皿：p53-V143A transfectant; 
p53-R273H transfectant. *: p<0.05; **: p<0.005. 
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Table 2.3.2 Summary of the basal expression profile of Jak/Stat signaling molecules 
in mutant p53 transfectants with respect to Saos-2 control cells. Key: represents 
similar expression between mutant p53 transfectants and control cells; 
•mr ‘ represents upregulation; ‘ -O^represents downregulation of the protein level 
when compared to the control cells. 
39 






ontrol • � 
53-V143A .. 、 
53-R273H 斗。\ $ 、 
2�义、卜寸 
0 ^ ^ 
U 1 0 5 10 15 20 25 
0 50 100 150 200 250 
b l I — — V 
u M 
Fig. 2.3.8 Sensitivity of Saos-2 cells to (A) AG490 and (B) Jak inhibitor 1. Cells were 
seeded for 2 days and incubated further with drugs for 5 days. Cell viability was 
determined by M T T assay. Standard deviation was obtained from more than 3 
separate experiments. •: Saos-2 control cells; •: Saos-2 p53-V143A transfectant; 
A : Saos-2 p53-R273H transfectant. 
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2.3.4 Janus kinases (Jaks) and IFN-alpha sensitivity in Saos-2 cells 
The relationship between Jaks and IFN-alpha sensitivity was studied by combined 
treatment of AG490 (Fig. 2.3.9) or Jak inhibitor 1 (Fig. 2.3.10) with IFN-alpha. 
AG490 and Jak inhibitor I both made the cells more resistant to the IFN-alpha 
treatment by the M T T assay. Thus, by inhibiting the activity of Janus kinases or Jak2 
only, cells became more resistant to IFNs, supporting that Jaks may play a role in 
IFN-alpha sensitivity in Saos-2 cells. 
The ability of IFN-alpha to transduce signals through the phosphorylation of Jakl, 
Statl and Stat2 is well known. The IFN-alpha induced Jak/Stat signaling in Saos-2 
cells was studied by Western blot analysis. Focus was put on the signaling molecules 
downstream of Jak2. They are Statl, Stat3, Stat5 and ISGF3gamma (Fig. 2.3.11). The 
specific phosphorylation levels of the Statl, Stat3 and Stat5 by IFN-alpha were 
determined by normalizing with the total protein level of the corresponding protein 
(Fig. 2.3.12). The basal Statl phosphorylation in Saso-2 cells was almost 
undetectable. Basal Jak2 phosphorylation seemed to be higher in the control cells 
than that in the mutant transfectants while basal Stat3 phosphorylation appeared to be 
higher in mutant p53 transfectant that than in the control cells. Basal Stat5 
phosphorylaiton seemed to be the same in all cells. IFN-alpha, AG490 or 
combination of both did not change the expression of Jak2, Statl, Stat3 and StatS 
significantly while ISGF3gamma was downregulated when treated with AG490 or 
combination of IFN-alpha and AG490. For Jakl, IFN-alpha alone or in combination 
with AG490 increased Jak2 phosphorylation in both control cells and mutant p53 
transfectants. IFN-alpha alone increased Statl phosphorylation in all cells while the 
presence of AG490 appeared to increase the IFN-alpha induced Statl 
phosphorylation in control cells while the drug seemed to suppress or have no effect 
in mutant transfectant. IFN-alpha also induced Stat3 phosphorylation and AG490 
4 1 
seemed to suppress on IFN-alpha induced Stat3 phosphorylation in all cells while the 
effect was more significant in mutant p53 transfectants. 
The mechanism through which Saos-2 cells gain resistance to IFN-alpha by 
inhibiting Jak2 was studied by D N A fragmentation assay of those cells which had 
undergone combined treatment of AG490 and IFN-alpha. AG490 at 25uM was rather 
low in toxicity and no significant D N A fragmentation could be observed in all cells. 
AG490 showed no significant effect on the extent of IFN-alpha induced D N A 
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Fig. 2.3.9 The effect of AG490 on the sensitivity of Saos-2 cells to IFN-alpha. Cells 
were seeded for two days to subconfluence and cells with or without incubation of 
IFN-alpha and AG490 alone or co-incubation of both were subjected to M T T assay 
after 5 days. Control (•): treatment with IFN-alpha only; 50uM AG490 (•): 
combined treatment with 50uM AG490 and IFN-alpha, survival was normalized with 
the toxicity of 50uM AG490; lOOuM AG490 (A): combined treatment with lOOuM 
AG490 and IFN-alpha, survival was normalized with the toxicity of lOOuM AG490. 
Standard deviation was obtained from more than 3 separate sets of experiments. 
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Fig. 2.3.10 The effect of Jak inhibitor I on the sensitivity of Saos-2 cells to IFN-alpha. 
Cells were seeded for two days to subconfluence and cells with or without incubation 
of IFN-alpha and Jak inhibitor I alone or co-incubation of both were subjected to 
M T T assay after 5 days. Control (•): treatment with IFN-alpha only; 0.75uM Jak 
inhibitor I (•): combined treatment with 0.75uM Jak inhibitor I and IFN-alpha, 
survival was normalized with toxicity of 0.75uM Jak inhibitor I; 1.5uM Jak inhibitor 
I (A): combined treatment with 1.5uM Jak inhibitor I and IFN-alpha, survival 
normalized with toxicity of 1.5uM Jak inhibitor I. Standard deviation was obtained 
from more than 3 separate sets of experiments 
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Fig 2.3.11 The effect of AG490 on IFN-alpha induced Jak/Stat signaling pathway 
activation in Saos-2 cells. Cells were seeded for 3 days to sub confluence. Cells with 
or without pretreatment of AG490 for 16 h was treated with IFN-alpha for 15 mins. 
Cells were lysed and resolved in SDS-PAGE, transferred to membranes and probed 
with specific antibodies. Signals were visualized under a X-ray film using the E C L 
system. Lane 1: control; lane 2: 16 hours preincubation with lOOuM AG490; lane 3: 
15 minutes stimulation by lOOOU/ml IFN-alpha; lane 4: 16 hours preincubation with 
100uMAG490 followed by 15 minutes stimulation by lOOOU/ml IFN-alpha. 
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Fig. 2.3.12 The effect of AG490 on IFN-alpha induced specific phosphorylation of 
Statl, Stat3 and Stat5. Cells were seeded for 3 days to sub confluence. Cells with or 
without pretreatment of AG490 was treated with IFN-alpha for 15 mins. Cells were 
lysed and resolved in SDS-PAGE, transferred to membranes and probed with specific 
antibodies. Signals were visualized under an X-ray film using the ECL system. The 
relative intensity is estimated by program Kodak Digital Science ID Scientific 
Imaging System. The specific phosphorylation of the molecules was calculated by: 
band intensity of phosphorylated form of that protein / band intensity of total level of 
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that protein. Relative specific phosphorylation was determined by specific 
phosphorylation in cells with treatment / specific phosphorylation in cells with no 
treatment. Lane 1: control; lane 2: 16 hours preincubation with lOOuM AG490; lane 
3: 15 minutes stimulation by lOOOU/ml IFN-alpha; lane 4: 16 hours preincubation 
with lOOuM AG490 followed by 15 minutes stimulation by lOOOU/ml IFN-alpha. 
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2.3.5 Janus kinases (Jaks) and IFN-gamma sensitivity 
Similar studies of using Jaks inhibitors in modulation of IFN-gamma sensitivity were 
conducted. AG490 made Saos-2 cells more resistant to IFN-gamma but had no effect 
on the response of p53-V143A and p53-R273H transfectants (Fig. 2.3.14). Jak 
inhibitor I however made both control cells and mutant p53 transfectants more 
resistant to IFN-gamma (Fig. 2.3.15). 
IFN-gamma stimulated Jak/Stat signaling was also studied (Fig. 2.3.16-7). AG490, 
IFN-gamma, or in combination appeared to have no effect on Jak2 phoshporylation 
in all cells. IFN-gamma was found to increase Statl phosphorylation in all cells and 
the increase was more significant in control cells. The IFN-gamma induced Statl 
phosphorylation however was suppressed by AG490. Similar finding was also 
observed for Stat3 phosphorylation. In the case of Stat5, both AG490 and 
IFN-gamma seemed to have minimal effect on the phophorylation of the molecules. 
IFN-gamma might not alter the level of ISGF3gamma but its level might be 
suppressed by AG490 alone or in combination with IFN-gamma. 
For apoptotic study, AG490 was found not to inhibit IFN-gamma induced D N A 
fragmentation in Saos-2 cells (Fig. 2.3.18). 
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Fig. 2.3.14 The effect of AG490 on the sensitivity of Saso-2 cells to IFN-gamma. 
Cells were seeded for two days to sub confluence and cells with or without 
incubation of IFN-gamma and AG490 alone or co-incubation of both were subjected 
to M T T assay after 5 days. Control (•): treatment with IFN-gamma only; 25uM 
AG490 (•): combined treatment with 25uM AG490 and IFN-gamma, survival was 
normalized with the toxicity of 25uM AG490; 50uM AG490 (A): combined 
treatment with 50uM AG490 and IFN-gamma, survival was normalized with 50uM 
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Fig. 2.3.15 The effect of Jak inhibitor I the sensitivity of Saos-2 cells to IFN-gamma. 
Cells were seeded for two days to subconfluence and cells with or without incubation 
of IFN-gamma and Jak inhibitor I alone or co-incubation of both were subjected to 
MTT assay after 5 days. Control ( • ) : treatment with IFN-gamma only; 0.75uM Jak 
inhibitor I { • ) : combined treatment with 0.75uM Jak inhibitor I and IFN-gamma. 
survival normalized with 0.75uM Jak inhibitor I toxicity; 1.5uM Jak inhibitor I ( A ) : 
combined treatment with l .SuM Jak inhibitor I and IFN-gamma. survival normalized 
with 1.5uM Jak inhibitor I toxicity. Standard deviation was obtained from more than 
3 separate sets of experiments 
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Fig 2.3.16 Effect of AG490 on IFN-gamma induced Jak/Stat signaling pathway 
activation in Saos-2 cells. Cells were seeded for 3 days to sub confluence. Cells with 
or without pretreatment of AG490 was treated with IFN-gamma for 15 mins. Cells 
were lysed and resolved in SDS-PAGE, transferred to membranes and probed with 
specific antibodies. Signals were visualized under a X-ray film using the ECL system. 
Lane 1: control; lane 2: 16 hours preincubation with lOOuM AG490; lane 3: 15 
minutes stimulation by lOOOU/ml IFN-gamma; lane 4: 16 hours preincubation with 
lOOuM AG490 followed by 15 minutes stimulation by lOOOU/ml IFN-gamma. 
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Fig 2.3.17 The effect of AG490 on IFN-gamma induced specific phosphorylation of 
Statl, Stat3 and Stat5. Cells were seeded for 3 days to sub confluence. Cells with or 
without pretreatment of AG490 was treated with IFN-gamma for 15 mins. Cells were 
lysed and resolved in SDS-PAGE, transferred to membranes and probed with specific 
antibodies. Signals were visualized under an X-ray film using the E C L system. The 
relative intensity is estimated by program Kodak Digital Science ID Scientific 
Imaging System. The specific phosphorylation of the molecules was calculated by: 
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band intensity of phosphorylated form of that protein / band intensity of total level of 
that protein. Relative specific phosphorylation was determined by specific 
phosphorylation in cells with treatment / specific phosphorylation in cells with no 
treatment. Lane 1: control; lane 2: 16 hours premcubation with lOOuM AG490; lane 
3: 15 minutes stimulation by lOng/ml IFN-gamma; lane 4: 16 hours preincubation 
with 1 OOuM AG490 followed by 15 minutes stimulation by 1 Ong/ml IFN-gamma. 
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Fig. 2.3.18 The effect of AG490 on IFN-gamma induced D N A fragmentation. Cells 
were seeded for 3 days to sub confluence. Cells with or without co-incubation of 
IFN曙gamma and AG490 were harvested after 72 h and subjected to D N A 
fragmentation assay. Lane 1: control; lane 2: treatment with 25uM AG490 for 72 
hours; lane 3: treatment with lOng/ml IFN-gamma for 72 hours; lane 4: treatment 
with lOng/ml IFN-gamma and 2 5 u M A G 4 9 0 for 72 hours. 
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2.4 Discussion 
There are growing evidences showing that mutation in the p53 gene leads to chemo-
and radio-resistance through gain of functions of the mutant p53 protein (Vasey et al. 
1996; Blandino et all999; Pugacheva et al. 2002; Soussi 2003; Zalcenstein et al. 
2003). W e are probably the first group to demonstrate that mutant p53 gains new 
functions involved in IFN resistance in Saos-2 cells. 
2.4.1 Mutant p53-V143 and p53-R273H induced IFN resistance in Saos-2 cells 
Saos-2 cells transfected with mutant p53-V143A and p53-R273H were more resistant 
to IFN-alpha and IFN-gamma treatment. This suggests a role for the mutant p53 in 
such resistance. Mechanistic study revealed that IFN-alpha and IFN-gamma could 
induce cell cycle arrest and apoptosis in Saos-2 cells that is devoid of wild-type p53. 
IFNs appeared to mediate apoptosis through activation of the caspase cascade in 
which caspase 8 and 3 were involved. Therefore, IFNs may induce apoptosis through 
a p53-independent pathway but depend on the extrinsic apoptotic pathway in Saos-2 
cells. By the cell cycle anaylsis and D N A fragmentation assay, mutant p53-V 143A 
and p53-R273H made Saos-2 cells less sensitive to IFNs, induced cell cycle arrest 
and apoptosis. By what pathway do the mutant p53 proteins act to attain such 
resistance? Gain of function studies suggest that mutant p53 proteins possess ability 
to regulate gene transcription that leads to drug resistance. Mutant p53 regulation of 
M D R l (Chin et al. 1992), dUTPase (Pugacheva et al. 2002) and CD95 (Zalcenstein 
et al. 2003) are just the few examples involved in drug resistance. It is reasonable to 
believe that mutant p53-V143A and p53-R273H may mediate IFN-alpha and 
IFN-gamma resistance through transactivation or transrepression of related genes. 
IFN resistance is related to the alteration in the IFN signaling pathway in quite a 
number of tumors. In general, defect in Jak/Stat pathway such as downregulation of 
the Jaks or Stats will lead to IFN resistance. For instance, T-cell lymphoma lack of 
56 
Statl expression is resistant to IFN-alpha (Sun et al. 1998; Landolfo et al. 2000). 
Therefore, this urges us to look into the Jak/Stat components in the mutant p53 
transfectants. Western blot analysis revealed that mutant p53-V143A and p53-R273H 
changed the basal protein expressions of some Jaks and Stats. The expression pattern 
was different between p53-V143A and p53-R273H. Therefore, such regulation seems 
to be mutant specific. It was also noted that there was a downregulation of some 
Janus kinases in mutant p53 transfectants, which are the most upstream effectors in 
the IFN signaling. p53-V143A seemed to downregulate Tyk2 while p53-R273H 
might downregulate Tyk2 and Jakl. Jak3 is basically not expressed in Saos-2 cells. 
Therefore, mutant p53 may induce IFN resistance through repression of these Janus 
kinases. 
2.4.2 Role of Jaks in IFN sensitivity in Saos-2 cells 
To confirm this notion, two Janus kinase inhibitors were used: AG490, a Jak2 
specific inhibitor and Jak inhibitor I, inhibitor of all the four Janus kinases. AG490 
and Jak inhibitor I made Saos-2 cells more resistant to IFN-alpha suggesting that by 
inhibiting Jak2 alone or all the four Jaks, cells became more resistant to IFN-alpha. 
This correlates with the downregulation of Tyk2 by p53-V143A and Tyk2 and Jak2 
by p53-R273H and may lead to IFN-alpha resistance subsequently. 
Similar results were obtained in the case of IFN-gamma. AG490 and Jak inhibitor I 
made Saos-2 cells more resistant to IFN-gamma. However, the effect was not 
significant in mutant p53 transfectants. This may be because mutant p53-V143A and 
p53-R273H were rather resistant to IFN-gamma already, further downregulation of 
Jaks may not make it even more resistant. Therefore, IFN-gamma resistance also 
correlates with the downregulation of Tyk2 in p53-V143A transfectant and Tyk2 and 
Jak2 in p53-R273H transfectant. 
2.4.3 IFN signaling in Saos-2 cells 
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As IFN sensitivity correlated with Jaks in Saos-2 cells, the IFN signaling was studied. 
IFN-alpha and IFN-gamma stimulated Jak2, Statl and Stat3 phosphorylation 
indicating an activation of the Jak/Stat pathway. The basal Stat3 phosphorylation was 
higher in the mutant p53 transfectants when compared to the control cells. This may 
contribute to IFN-alpha and -gamma resistance. In IFN-gamma signaling, 
IFN-gamma induced Statl phosphorylation was lower in mutant p53 transfectants 
indicating that the IFN-gamma induced signaling was impaired in mutant cells. This 
may also contribute to IFN-gamma resistance in Saos-2 cells. Further experiments 
have to be done to confirm this claim. 
AG490 could inhibit the IFN-gamma induced phosphorylation of Statl and Stat3 but 
not that by IFN-alpha. As AG490 is a Jak2 specific inhibitor, IFN-gamma signals 
may be transduced through Jak2 while that may not be the case for IFN-alpha. This 
agrees with the present knowledge on IFN signaling. As IFN-alpha induces Stat 
protein phosphorylation through Tyk2 and Jakl, AG490 would not inhibit 
phosphorylation of the Stat proteins through these kinases. On the other hand, 
IFN-gamma induces Stat protein phosphorylation through Jakl and Jak2, inhibition 
of Jak2 impairs Stat protein phosphorylation. This may suggest that p53-R273H 
downregulation of Jak2 may impair IFN-gamma signals and leads to IFN-gamma 
resistance in Saos-2 cells. 
2.4.4 Jak2 and IFN induced apoptosis 
The role of Jak2 in IFN induced apoptosis was studied to see if it correlated with its 
role in IFN sensitivity and signaling. AG490 may not alter the IFN-alpha and 
IFN-gamma induced D N A fragmentation. Therefore, Jak2 may not be involved in 
IFN sensitivity through the regulation of IFN mediated apoptosis in Saos-2 cells. 
Other pathway could be involved like the regulation cell cycle or cell survival. 
These data at least suggest that IFN-alpha and IFN-gamma resistance maybe 
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Chapter 3 Mutant p53 induced drug resistance 
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3.1 Introduction 
3.1.1 The multidrug resistance (MDR) 
Multidrug resistance (MDR) is the protection'of a tumor cell population against 
numerous drugs differing in chemical structures and cytotoxic mechanisms on the 
cells (Stavrovskaya 2000). There are two kinds of M D R , the intrinsic M D R and 
acquired M D R . The intrinsic M D R refers to cell population that is resistant to 
anticancer drugs before chemotherapy. Examples are melanomas, lung and 
pancreatic cancers (Soengas and Lowe 2003). Acquired M D R arises in the course of 
chemotherapy. Rare genetic variants of drug resistant cells can occur in a tumor cell 
population under the influence of drug, and these cells can multiply if they have 
selective advantage. Selective advantage may be the result of both the drug resistance 
and of other traits: acceleration of proliferation rate, alterations of cell sensitivity to 
growth factors, etc. Acquired M D R , arising during the course of treatment, is 
common in relapsing leukemia, ovarian and breast carcinoma and involves similar 
mechanisms to those of intrinsic resistance (Pommier et al. 2004). 
There are various mechanisms involved in M D R . The best characterized mechanism 
is the active efflux of drugs leading to a decrease of drug accumulation in cells. Drug 
efflux from cells is mediated by the activity of energy-dependent ATP-binding 
cassette (ABC) transporter proteins such as P-glycoprotein (P-gp), multidrug 
resistance-associated protein (MRP) and some other proteins (Table 3.1.1). 
P-gp, encoded by the M D R l gene, is a 170 kD transmembrane protein that may 
function as flipase and move bound substance outside the cell (Higgins et al. 1997). 
P-gp is also expressed in normal tissues such as cells of the cortex of adrenal gland, 
mucosal cells of the colon, etc (Roninson 1990). P-gp expression is regulated by 
numerous pathways. For instance, p53, ras, raf, R A R a and RAR(3 altered the M D R l 
promoter activity (Teeter et al. 1991; Chin et al. 1992; Stromskaya et al. 1998), c-fos 
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and c-jun were also shown to influence M D R l activity (Bhushan et al. 1992; Bosh 
and Croop 1996) and protein kinases C and A were shown to involve in regulation of 
P-gp activity (Chaudhary and Roninsin 1992; Bosh and Croop 1996). 
Overexpression of P-gp confers resistance to a variety of structurally and 
functionally unrelated anticancer drugs such as vinblastine, vincristine, doxoruicin, 
daunorubicinl, etoposide, teniposide, paclitaxel and many others (Sugimoto and 
Tsumo 1987). Another A B C transporter is the M R P which is a 190 kD protein. M R P 
requires cellular glutathione for its function as a drug effluxing pump. M R P 
determines the resistance of cells almost to the same substances as P-gp. 
Overexpression of M R P also confers multidrug resistance, for example, in chronic 
lymphoid leukemia (Stavrovskaya 2000). 
M D R could also be mediated by upregulation of genes involved in detoxification of 
the drug in cells. The glutathione (GSH) system is a crucial detoxification system in 
cells. It consists of an enzyme glutathione S-transferase (GST) that catalyses the 
interaction between glutathione and alkylating agents such as melphalan, 
cyclophosphamide, chlorambucil and cisplatin, resulting in conjugation of the drug 
with glutathione. The conjugate is less active, more water-soluble and is excluded 
from the cell with the participation of transporter proteins known as GS-X. Increased 
G S T activity correlated with patients demonstrating M D R such as in 
chlorambucil-resistant chronic lymphocytic leukemia (Schisselbauer et al. 1990). 
Drug resistance could also be mediated by alterations in drug target or by 
enhancement of target repair. Many anticancer drugs target at enzymes involved in 
cellular pathway. Alteration of the drug target enzymes changes response to the drug. 
For instance, some anticancer drugs are inhibitors of topoisomerases (topoisomerase 
I or topoisomerase II). These drugs stabilize the DNA-topoisomerase complex which 
in normal circumstances is easily decomposed. In cell lines selected for the resistance 
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to topoisomerase Il-inhibiting drugs, the activity or the quantity of this enzyme are 
reduced. Another probable way to induce drug resistance is an increase in the 
quantity of target protein in cells. For example*, in a number of cultured cell lines 
resistant to methotrexate, there was an increased level of dihydrofolate reductase 
(DHFR) which is the target protein of methotrexate. Enhanced D N A repair is 
implicated in drug resistance to drug that interact with D N A , for example, 
nitrosomethylurea or platinum derivatives. Changes in quantities of proteins 
recognizing and repairing D N A injuries (ERCCl, E R C C 2 and ERCC3/XPB) were 
found in cultured cells with altered sensitivity to platinum complexes (Chu 1994). 
M D R could also be mediated by alteration in signaling pathways. Two well-known 
pathways that correlate with M D R are the apoptotic pathway and the survival 
pathway. Most chemotherapeutic drugs induce apoptosis through the intrinsic 
pathway that involves outer mitochondrial membrane permeabilization. This event is 
under the control of the Bcl-2 proteins family. Mitochondrial membrane 
permeabilization leads to the leakage of cytochrome c’ Smac/DIABLO, HtrA2/0mi, 
apoptosis inducing factor (AIF) and endonuclease G (Endo G) from the 
mitochondrial intermembrane space (Ravagnan et al. 2002). In the cytosol, 
cytochrome c induces the oligomerization of apoptosis protease activating factor-1 
(Apaf-1) in the presence of ATP or dATP (Li et al. 1997; Hu et al. 1999). Apaf-1 
oligomers recruit pro-caspase-9 molecules to form a complex called the 'apoptosome' 
where they are activated (Srinivasula et al. 1998; Saleh et al. 1999). The release of 
mature caspase-9 activates additional caspase-9 molecules and also effector caspases, 
caspase-3 and -7. Caspase-3 activates downstream caspase cascades (Slee et al. 
1999). The release of Smac/DIABLO and HtrA2/0mi neutralize the inhibitory effect 
of inhibitors of apoptosis proteins (lAPs) on caspase-3, -7 and -9 (Deveraux et al. 
1999; Vaux and Silke 2003) whereas AIF and Endo G directly induce nuclear 
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modifications. Chemotherapeutic agents may also activate the extrinsic apoptotic 
pathway that involves the trimerization of the Fas with Fas ligand and recruits F A D D 
(Chinnaiyan et al. 1995) and pro-caspase 8 (Medema et al. 1997) to form a complex 
called death-inducing signaling complex (DISC). Pro-caspase oligomerization 
autoactivates and release mature caspase 8 (Salvesen and Dixit 1999) and may 
induce apoptosis either through direct activation of caspase-3 and downstream 
caspase cascade when active caspase 8 is in high level; or, when caspase 8 is in low 
level, it may cleave Bid to form t-Bid, which is a member of proapoptotic Bcl-2 
protein, and activate the mitochondrial apoptotic pathway (Li et al. 1998; Luo et al. 
1998). Therefore, alteration in the components of the drug mediated apoptotic 
pathway affects the response of cells to the drugs. For example genes in the Bcl-2 
family contribute to M D R in tumors. Bcl-2 family encodes for both pro-apoptotic 
proteins (Bax，Bak, Mtd (Bok), Bcl-rambo, Bad, Bid, Noxa, Puma, Bik (Nbk), Bim 
(Bod), Hrk (DP5), Blk, Bmf, Bnip3 (nix), pi93 and Bcl-G) and anti-apoptotic 
proteins (Bcl-2, BC1-XL, Bcl-w, Mcl-l, Bfl-l (Al) and Boo (Diva). The balance of the 
pro- and anti-apoptotic Bcl-2 proteins control the drug induced mitochondrial 
membrane permeabilization and apoptosis subsequently. Bcl-2 protein family 
deregulation often occurs in cancer and may lead to M D R . Bcl-2 overexpression is 
one of the examples, which was initially described in follicular lymphomas as a 
consequence of a t(14;18) translocation. It is also found in prostate, breast and colon 
carcinomas. Upregulation of Mcl-l, an anti-apoptotic Bcl-2 protein, was identified in 
acute myelogenous leukemia (AML). Alteration in the death receptor pathway and 
thus induction of M D R are described in some malignancies. It was shown that 
lymphocytes of mice with mutation in gene encoding Fas-L are resistant to a number 
of chemotherapeut ic drugs (Friezen et al. 1996; Landowski et al. 1997; Reap et al. 
1997). 
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M D R could also be mediated by alteration in signaling pathways. One of the most 
well known is the involvement of survival pathways in drug resistance including the 
A K T mediated and the N F - K B mediated survival signaling pathways. 
Besides the chemotherapeutics induced pro-apoptotic signals, the susceptibility of 
cells to drug induced apoptosis would also depend on the survival signals. Mitogens 
such as cytokines and growth factors, bind to receptor kinases and activate the 
phosphoinositide 3-kinase (PI3K) (Cantley 2002). Active PI3K converts the lipid 
PIP2, into PIP3 and activates the AKT/ protein kinase B. A K T regulates various 
downstream targets involved in apoptosis, cell cycle, D N A repair, nitric acid 
production and glycogen metabolism (Vivanco and Sawyers 2002) that promotes cell 
survival, cell proliferation and migration. They include transcription of BC1-XL, 
inactivation of the transcription factor F K H R L l (an inducer of a number of 
pro-apoptotic factors), inactivation of Bad, pro-caspase 9, etc. A K T can also activate 
the N F - K B survival functions (Cantley 2 0 0 2 ) . P T E N is a negative regulator of the 
A K T survival pathway by dephosphorylating PIP3 (Maehama et al. 2001). 
Deregulation of AKT-mediated survial signaling leads to resistance to chemotherapy. 
Fibroblasts overexpressing A K T in lung cancer cells are resistant to staurosporine-
and etoposide-induced apoptosis (Tang et al. 2001; Karpinich et al. 2002). Cell lines 
deficient in PTEN and PTEN-knockout mice are resistant to drug induced apoptosis 
(Wu et al. 2003). 
Nuclear factor KB is a family of transcription factors that bind to genes with KB sites 
and stimulate expression of genes suppressing apoptosis, promoting cell growth, 
stimulating immune responses and functioning in negative feedback (Karin et al. 
2002). N F - K B mediates its anti-apoptotic function by stimulating expression of the 
inhibitors of apoptosis proteins (lAPs), which bind and inhibit caspases (Burks et al. 
1998； Deveraux et al. 1998) and of c-FLIP (Flice (caspase 8)-inhibitory protein) 
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which blocks caspase 8 activity (Micheau et al. 2001); expression of Bcl-2 homologs 
Al/Bfl-L (Budihardjo et al. 1999) and BCI-XL (Chen et al. 2000); expression of the 
adaptor molecules (TRAF-1, TRAF-2) (Baldwin* 1996), etc. 
M D R is mediated through multiple mechanisms, the drug efflux, the enhanced 
detoxification system, alteration of target genes, D N A repair genes and apoptosis and 
survival signaling. However, it is still unclear which is predominant pathway in 
M D R and more than one pathway may operate in the same cell. Moreover, the 
mechanism of resistance may differ in particular cell type in response to particular 
drug. For example, cisplatin resistance can be connected with the activation of 
glutathione system, increased efflux of the drug, alterations in apoptosis regulation 
and increased D N A repair (Chu 1994). Therefore, this arouses our interest in 
studying the role of p53 mutation, which is such a common phenomenon in cancer, 
in M D R . 
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3.1.2 Anticancer drugs used in the study: action mechanisms and resistance 
To study the role of mutant p53 in M D R , several common anticancer drugs with 
different mechanisms of action have been chosen. They are camptothecin (CAM), 
methotrexate (MTX), tamoxifen (TAM), taxol (TAX) and vincristine (VCR), which 
are summarized in Table 3.1.2. Their structures are shown in Fig. 3.1.1. 
Camptothecin is a reversible D N A topoisomerase I inhibitor that binds to and 
stabilizes the topoisomerase-DNA covalent complex. The topoisomerase 
I-camptothecin-DNA cleavable complex block the replication fork in mitosis and 
result in S phase arrest or G2 arrest subsequently. Resistance to camptothecin may 
involve reduced enzymatic activity of or quantity in topoisomerase I (Pommier et al. 
1994). 
Methotrexate inhibits dihydrofolate reductase and inhibits the de novo purine 
synthesis and thus inhibits D N A synthesis. Resistance to M T X includes an increase 
in the quantity of dihydrofolate reductase and thymidylate synthetase. 
Tamoxifen has been used to treat estrogen-dependent breast cancer due to its 
antiestrogenic activity, mediated by competitive inhibition of estrogen binding to 
estrogen receptors (Osborne et al. 1996) and thus inhibiting the expression of 
estrogen-regulated genes, for instance, growth factor and angiogenic factors secreted 
by the tumor in auto or paracrine manner (Arteaga et al. 1991). It may also inhibit the 
activity of protein kinase C. The consequence is cell cycle arrest at G1 or apoptosis 
(Ellis et al. 1997). Tamoxifen resistance is associated with estrogen-independent 
growth of tumor cells. 
Taxol promotes assembly of microtubules and inhibits tubulin disassembly. It causes 
G2 phase arrest in some cells like HeLa and B16 cells and induces apoptosis. 
Vincristine on the other hand inhibits the formation of microtubules and 
depolymerizes microtubules. It therefore could also delay cell cycle progression and 
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induce apoptosis. Taxol and vincristine are the substrates for P-gp. Overexpression of 
P-gp may correlate with taxol and vincristine resistance. 
3.1.3 Jak/Stat pathway and MDR 
The Jak/Stat pathway is well documented for its role in cytokine signaling. It is 
associated with the IFN induced cell cycle arrest and apoptosis as introduced in 
Chapter 3. The ability of Stat proteins in controlling drug induced apoptosis has also 
been demonstrated. Statl has been implicated as a tumor suppressor. It is required in 
apoptosis and growth arrest of some cell types through its ability to upreuglate 
caspases, Fas，FasL and p2lWAFi/ciPi ^ nd (Lee et al. 2000; Ouchi et al. 2000; 
Agrawal et al. 2002). It also cooperates with wild-type p53 through its C-terminus to 
induce apoptosis in response D N A damage (Twonsend et al. 2004). 
Doxorubicin resistance in human neuroblastoma is due to inhibition in apoptosis 
mediated by activation of Stat3 (Rebbaa et al. 2001). StatS is required for the 
expression of the antiapoptotic genes survivin and BCI-XL in glioblastoma cell line 
(Konnikova et al. 2003). However, study on the role of Jak/Stat pathway in drug 
sensitivity and resistance is still limited. 
In this chapter, the role of mutant p53 in M D R will be investigated by testing the 
sensitivity of Saos-2 cells with or without transfection of mutant p53 to the common 
anticancer drugs. The mechanism by which mutant p53 transfectants gain drug 
resistance will be studied by their responses to drug induced apoptosis and cell 
cycle arrest. As demonstrated in Chapter 2, mutant p53 may transregulate the 
expressions of Jaks and Stats and Jaks play a role in IFN sensitivity. Moreover, 
Statl and StatS are implicated in the drug induced apoptosis. Therefore, it is 
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speculated that mutant p53 may also induce drug resistance through Jak/Stat pathway. 
The role of Jaks in drug sensitivity will also be studied. 
» 
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Protein Molecular Human gene Chromosome 
weight, k D localization 
P-glycoprotein (P-gp) 140-170 . M D R l 7q2Ll 
M R P 190 M R P l 16ql3.1 
L ^ 110 — L R P 16qll.2 
V M A T (vesicular 62 V M A T 10q26.1 
monoamine transporter)  
ARX 72 |aRX |lq22 
Table 3.1.1 Examples of multidrug transporters (proteins and genes coding the 
transporters) (Stavrovskaya 2000). 
Families of Drugs Mechanism of Target molecules 
anticancer drug action  
Antimetabolites Methotrexate Inhibit de novo Dihydrofolate 
(MIX) purine synthesis in reductase and 
D N A synthesis thymidylate 
synthetase 
Anticancer Camptothecin Topoisomerase Topoisomerase I 
antibiotics ( C A M ) inhibitor  
Drugs derived from Taxol (TAX) Inhibit tubulin Tubulin 
plants dissembly 
Vincristine (VCR) Inhibit formation of Microtubules 
microtubules  
Antiestrogen Tamoxifen (TAM) Inhibit estrogen Estrogen receptor 
functions and protein kinase C 
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Fig. 3.1.1 Structures of anticancer drugs used in this study (www.calbiochem.com). 
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3.2 Materials and methods 
3.2.1 Cell lines 
The cell lines used were human osteosarcoma Saos-2 cells. For details, refer to 
chapter 2.2. 
3.2.2 Drugs and antibodies 
AG490, JAK inhibitor I (Jakil), tamoxifen (Calbiochem, Germany), camptothecin, 
methotrexate, taxol, vincristine (Sigma, U S A ) were employed. The primary 
antibodies used in the Western Blot analysis included anti-JAKl, JAK2, JAK3, 
TYK2, STATl, STAT2, S T A B , STAT4, STAT5, STAT6, ISGF3y (BD Transduction 
Laboratories), p-JAK2, p-STATl, p-STAT3, p-STAT5, Caspase 3, Caspase 8, 
Caspase 9, Topol (Santa Cruz Biotechnology Inc., USA). 
3.2.3 Caspase 3 activity assay 
Cells were tripsinized, washed with phosphate buffered saline (PBS) and centrifuged 
after drug treatment. The cell pellets were resuspended in 25ul of lysis buffer (100 
m M NaCl, 5 ug/ml aprotinin, 10 ug/ml leupetin, 0.1 m M EDTA, 50 m M HEPES, 
0.1% CHAPS, 0.1 m M D T T and 100 u M PMSF). Total cell lysates were then 
equilibrated with assay reaction buffer (100 m M NaCl, 50 m M EDTA, 50 m M 
HEPES, 0.1% CHAPS, 10 m M DTT, 10% glycerol) at 37 °C for 10 min. Catalytic 
activity of caspase-3 was measured by proteolytic cleavage of 10 u M substrate 
Ac-DEVD-pNA for up to 2 h. The release of p N A was measured 
spectrophotometically by absorbance at 405 nm with assay reaction buffer as blank. 
The specific caspase 3 activity was normalized by B C A Protein Assay Reagents 
(Pierce). 
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3.2.4 Cell Proliferation assay- MTT assay 
Refer to chapter 2.2. 
3.2.5 Cell cycle analysis 
Refer to chapter 2.2. 
3.2.6 DNA fragmentation assay 
Refer to chapter 2.2. 
3.2.7 Reverse transcription polymerase chain reaction 
Total R N A was isolated by lysing cells with TRI R E A G E N T (Molecular Research 
Center). Cells were lysed by pipetting up and down several times. R N A was 
extracted with 1 -bromo-3 -chloropropane (BCP)(Molecular Research Center) and 
precipitated with isopropanol. Pellet was washed once with 75% ethanol treated with 
diethyl cyanophosphonate (DEPC) and was dissolved in D E P C treated water by 
incubating for 10 min at 55-60。C. R N A integrity was checked by preservation of 18 
and 28S R N A visualized after gel electrophoresis. R N A was quantified 
spectrophotometrically by absorbance at 260nm. 
2.5 ug of total R N A was used for synthesis of the first strand cDNA. Total R N A was 
incubated with 0.25 ug oligo dT (Invitrogen) and 200 u M dNTP mix for 5 minutes at 
70。C and then kept at ice for 2-3 min. The first strand c D N A was synthesized by 
M - M U L V R T (Pormega) in IX first strand RT buffer for 60 minutes at 42。C. 
The gene of interest was amplified by gene specific primers (100 nM) with IX PGR 
buffer, 2 m M MgCb, 200 n M dNTP and 1.25 U Taq D N A polymerase (Promega). 
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The primers used were: 
Gene Primer sequence Gene Size of band 
• homology 




了3 5'-TTTTGGAGGAGTTGCTGTGG (forward) =51 -767 516 
5'-TGTGCATCTCCCAAAGTGTG (reverse) 
p-actin 5 ' - G C G G G A A A T C G T G C G T G A C A T T 686-919 233 
(forward) 
5 ' G A T G G A G T T G A A G G T A G T T T C G T G 
(reverse) 
3.2.8 Western blot analysis 
Refer to chapter 2.2. 
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3.3 Results 
3.3.1 Mutant p53 and drug sensitivity 
To study the role of mutant p53 in multidrug resistance, the sensitivity of Saos-2 
control cells and mutant p53 transfectants to common anticancer drugs were tested 
by using the M T T assay. The results showed that mutant p53-V143A and p53-R273H 
made the cells more resistant to camptothecin, methotrexate, tamxifen and vincristine 
while p53-V143A made the cells more resistant to taxol in Saos-2 cells (Fig. 3.3.1). 
The IC50 values are summarized in Table 3.3.1. 
3.3.2 Mutant p53 and drug induced apoptosis and cell cycle arrest 
Many anticancer drugs exert their antitumor and antiproliferative effects by inducing 
apoptosis and cell cycle arrest. Resistance to these drugs may be due to the resistance 
to drug induced apoptosis and/or cell cycle arrest. To study the mechanism by which 
mutant p53 induced drug resistance, the drug induced apoptosis and cell cycle arrest 
were studied by D N A fragmentation assay and cell cycle analysis. D N A 
fragmenation assay showed that mutant p53 transfectants were more resistant to 
C A M , M T X and T A X induced D N A fragmentation than the control cells. It is noted 
that although the sensitivities of Saos-2 control cells and p53-R273H transfectant to 
T A X were similar, p53-R273H seemed to be less sensitive to T A X induced D N A 
fragmentation than the control cells (Fig. 3.3.2). The results from the cell cycle 
analysis also supports this notion. The drugs induced sub-Gl peaks and cell cycle 
arrest at S phase were less significant in mutant p53 transfectants than that in the 
control cells (Fig. 3.3.3). 
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Fig. 3.3.1 Sensitivity of Saos-2 cells to common anticancer drugs: camptothecin, 
methotrexate, tamoxifen, taxol and vincristine. Cells were seeded for 2 days and 
drugs were added for incubation for further 5 days. Cell viability was determined by 
M T T assay. Standard deviation was obtained from more than 3 separate experiments. 
• : Saos-2 control cells; •: Saos-2 p53-VI43A transfectant; A : Saos-2 p53-R273H 
transfectant. 
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[control cells [p53-V143A |p53-R273H 
C A M (ng/ml) 2 4 . ^  
M T X (nM) H ^ n  
T A M (uM) 17^ 17^ 
T A X (ng/ml) 5 8 5 
V C R (ng/ml) (2 [s p 
Table 3.3.1 IC50 values of anticancer drugs in Saos-2 cells. 
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(A) C A M Control p53-V143A p53-R273H 
1 2 3 1 2 3 1 2 3 
B H 
(B) M T X 
Control p53-V143A p53-R273H 
mam • • • 
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^ m • • 害 葡 WB 贊 ^ • 
Control cells p53-V143A p53-R273H 
(E) V C R 
1 2 3 1 2 3 1 2 3 
Fig. 3.3.2 Drug induced D N A fragmentation in Saos-2 cells. Cells were seeded for 3 
days to sub confluence. Drugs were added and further incubated for 3 days. Cells 
were then harvested and subjected to D N A fragmentation assay. (A) C A M induced 
D N A fragmentation. Lane 1: control; lane 2: 2.5 ng/ml C A M ; lane 3: 5 ng/ml C A M . 
(B) M T X induced D N A fragmentation. Lane 1: control; lane 2: 25 n M M T X ; lane 3: 
50 n M M T X . (C) T A M induced D N A fragmentation. Lane 1: control; lane 2: 15 u M 
T A M ; lane 3: 17.5 u M T A M . (D) T A X induced D N A fragmentation. Lane 1: control; 
lane 2: lOng/ml TAX; lane 3: 25 ng/ml TAX. (E) V C R induced D N A fragmentation. 
Lane 1: control; lane 2: 2.5 ng/ml VCR; lane 3: 5 ng/ml V C R . The experiments were 
repeated for three times and similar results were obtained. The one shown was the 
representative one. 
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Fig. 3.3.3 The cell cycle distribution in Saos-2 cells after drug treatment as analysed 
by flow cytometry. Sub confluent cells were treated with (A) 2.5 ng/ml C A M ; (B) 25 
n M M T X ; (C) 15 u M T A M ; (D) 15 ng/ml TAX; (E) 2.5 ng/ml V C R for 16, 24, 48 
and 72h. Cells were fixed with 70% ethanol and stained with propidium iodide. 
Subdiploid D N A was measured by FACSort flow cytometer and analyzed by 
software WinMDI 2.5. Red area: control; Black line: treatment with drugs. •: 
sub-Gl; Gl;圓：S; _ : G2/M phases in cell cycle. The experiments were 
repeated once and similar result was obtained. The one shown was the representative 
one. 
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3.3.3 Classical drug resistance factors in mutant p53 induced drug resistance 
To further elucidate the mechanisms of mutant p53 induction of drug resistance, 
genes that are known to be related to resistance to some common anticancer drugs 
were studied. 
C A M is a topoiosmearase I (Topo I) inhibitor. One possible mechanism to induce 
C A M resistance is downregulation of Topo I. By Western blot analysis, it seemed 
that the level of Topo I expression was similar in the control cells and mutant p53 
transfectants (Fig.3.3.4). 
M T X inhibits D H F R and its resistance is correlated with overexpression of 
dihydrofolate reductase (DHFR) and thymidylate synthetase (TS) in resistant cells. 
The m R N A expression levels of TS and D H F R were studied by RT-PCR. The results 
showed that the expression levels in TS and D H F R were similar between the Saos-2 
control cells and mutant p53 transfectants (Fig. 3.3.4). 
Therefore, it seems that mutant p53-V143A and p53-R273H may not mediate C A M 
and M T X resistance through regulation of these genes. Other pathway may be 
involved. 
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Fig. 3.3.4 Basal protein expression of topoisomerase I (Topo I) and m R N A 
expression of dihydrofolate reductase (DHFR) and thymidylate synthetase (TS) in 
Saos-2 cells. For protein expression of Topo I, sub confluent cells were lysed for 
protein, resolved in SDS-PAGD gel and transferred to a membrane. The membrane 
was probed with anti-Topo I antibody and visualized on an X-ray film using the E C L 
system. For the m R N A expression of D H F R and TS, sub confluent cells were lysed 
for R N A and reverse transcribed to cDNA. Gene specific primers, DHFR: 
5'-CACCGCTCAGGAATGAATTGAGATA (forward), 5'-
GGGTGATTCATGGCTTCCTTATAAACAG (reverse); TS: 
S'.TTTTGGAGGAGTTGCTGTGG (forward) 
5'-TGTGCATCTCCCAAAGTGTG (reverse); p-actin: 
5 ' G C G G G A A A T C G T G C G T G A C A T T (forward); 
5 ' G A T G G A G T T G A A G G T A G T T T C G T G (reverse), were used to amplified the 
transcripts. m R N A levels were visualized by gel electrophoresis in agarose gel 
stained with ethidium bromide. 
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3.3.4 The role of Jaks in drug sensitivity of Saos-2 cells 
There is evidence showing that Jak/Stat pathway may be involved in drug sensitivity, 
for example, Statl and Stat3 control apoptosis in'response to D N A damage. And also, 
in previous chapter, it was found that mutant p53 was able to regulate the expressions 
of Jaks and Stats and Jaks played a role in IFN sensitivity. Hence, it is speculated that 
Jaks may also have a role in drug sensitivity in Saos-2 cells. 
The Jak2 specific inhibitor, AG490, and the Janus kinase inhibitor, Jak inhibitor I, 
were used to confirm this notion. The results showed that AG490 made both control 
cells and mutant p53 transfectants significantly more resistant to M T X while it 
slightly made all the cells more resistant to C A M at 50uM. AG490 at 50uM also 
made all the cells more resistant to higher dosage of V C R (i.e. higher than 5ng/ml) 
(Fig. 3.3.5). AG490 made the control cells and p53-R273H transfectant slightly 
resistant to T A X but the effect was more significant in p53-V143A transfectant. 
AG490 seemed not to modulate T A M sensitivity of Saos-2 cells. Jak inhibitor I made 
Saos-2 cells more resistant to C A M and M T X and also to a higher dose of V C R (i.e. 
higher than 5ng/ml) in control cells and p53-V143A, but Jak inhibitor I made 
p53-R273H cells slightly more sensitivite to V C R at a lower dose (i.e. lower than 
5ng/ml). Whereas, Jak inhibitor I appeared to have no effect on T A M and T A X 
sensitivity of Saos-2 cells (Fig. 3.3.6). This confirms the role of Jaks in drug 
sensitivity, especially in M T X sensitivity. 
3.3.5 The role of Jaks in drug induced DNA fragmentationin Saos-2 cells 
To elucidate the mechanism by which Jak2 inhibitor, AG490, made the cells resistant 
to M T X , D N A fragmentation assay was carried out in Saos-2 control cells and 
mutant p53 transfectants after combined treatment of AG490 and drugs. AG490 was 
rather non-toxic and no D N A fragmentation was seen apparently. M T X obviously 
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induced D N A fragmentation and AG490 significantly suppressed the M T X induced 
D N A fragmentation (Fig. 3.3.7). Such suppression was not observed in other drugs. 
Therefore, AG490 may make the cells resistant to M T X through suppression of M T X 
induced apoptosis. Such phenomenon was not observed in other drugs. AG490 
slightly increased the extent of C A M induced D N A fragmentation in control cells 
and p53-V143A transfectant but not in p53-R273H transfectant and AG490 did not 
appear to change the V C R induced D N A fragmentation in all cells. AG490 increased 
T A M and T A X induced D N A fragmentation in the control cells. In the case of TAX, 
AG490 also increased T A X induced D N A fragmentation in p53-V143A and 
p53-R273H. Therefore, the effect of AG490 on C A M , T A M , T A X and V C R induced 
D N A fragmentation in Saos-2 cells did not correlate with the effect of combined 
treatment of these drugs and AG490 on survival. 
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Fig. 3.3.5 The effect of AG490 on the sensitivity of Saos-2 cells to C A M , M T X , 
T A M， T A X and V C R . Cells were seeded for two days to sub confluence and cells 
with or without incubation of drugs and AG490 alone or co-incubation of both were 
subjected to M T T assay after 5 days. Control (•): treatment with drug only; 25uM 
AG490 (•): combined treatment with 25uM AG490 and drug, survival was 
normalized with toxicity of 25uM AG490; 50uM AG490 (A): combined treatment 
with 50uM AG490 and drug, survival was normalized with toxicity of 50uM AG490. 
Standard deviation was obtained from more than 3 separate sets of experiments. 
93 
(A) C A M 
Control cells p53-V143A p53-R273H 
120 t Control 1 2 0 � 120 
- B - 0 . 7 5 u M Jak inhibitor I 
» 
l O O l L • • - l - S u M J a k m h M o r l _ 啓 
80 A 80 X - i 80 
60 H 60 60 
40 y l ^ L 40 40 ^ ^ ^ ^ 
20 V $ • 20 ^ ^ 20 
0 5 10 15 0 5 10 15 0 5 10 15 
ng/ml 
(B) M T X 
120 •^^"Control 120 120 
• O 0.75uM Jak 
inhibitor I -- „„ r =1 
lOOH • ^ 1.5uMJak lOOil lOOilLU 
T ^ inhibitor I ^ n 
% 。！T 
60 I 60 \、牟 60 Y\ 
40 [飞®玉认 40 V ^ Q 40 L y ^ -
.0 ^ P 2 。 〜 2 。 购 
-^ i L 0 丄 ^^^^^^^ Q L 」 I 0 1 」 
I 0 50 100 150 0 50 100 150 0 50 100 150 
• n M 
^ Drug conc. 
94 
(C) TAM 
Control cells p53-V143A p53-R273H 
120 > Control 1 2 0 � ‘ 1 2 0 
• Q - 0 . 7 5 u M Jak inhibitor I ^ ^ 
1 0 0 ^ ^ 知 1 .5uM Jak inhibitor I l O O H ^ * 1 0 0 ^ ^ - ^ 
8 0 I 8 0 8 0 
60 * 孤 60 - 等T 60 -
\ \ t 40 - I 40 - t 40 • J I 
20 3L 20 - Ip 20 1 I 
% % w 
0 丨 ^ 」 0 j ^ — — — - - 」 0 L 丨 彳 I 
0 10 20 30 0 10 20 30 0 10 20 30 
u M 
(D)TAX 
1 2 0 i Control 1 2 0 - 1 2 0 
_ • • 0 .75uM Jak inhibitor I • 
• 一 1.5uMMin_。rI •華 lOOj 丨 
4 七 8。 
60 I 6 。 6 。 ^ 
\ 。 ％ ^ i I 
“ V S | _ L 4 �1 ^ — I 
. 0 20 40 60 0 20 40 60 0 20 40 60 
I ng/ml 
< ^ 
一 Drug conc. 
95 
(E) VCR 
Control cells p53-V143A p53-R273H 
120 _ Control 120 120 
• 0 . 7 5 u M Jak inhibitor I 
1 0 0 | i “ — 1 . 5 - M inhibitor I 1 0 0 | H 
80 I 80 X 80 
\ \ \ 
60 g 60 7|Y ^ A i 60 ® 
恥 I � - F W 
20 20 20 
^ 0 5 10 15 0 5 10 15 0 5 10 15 
g • ng/ml 
^ Drug conc. 
Fig 3.3.6 Cells were seeded for two days to sub confluence and cells with or without 
incubation of drugs and Jak inhibitor I alone or co-incubation of both were subjected 
to M T T assay after 5 days. Control (•): treatment with drug only; 0.75 u M Jak 
inhibitor I (•): combined treatment with 0.75 u M Jak inhibitor I and drug, survival 
was normalized with 0.75uM Jak inhibitor I; 1.5 u M Jak inhibitor I (A): combined 
treatment with 1.5 u M Jak inhibitor I and drug, survival was normalized with L 5 u M 
Jak inhibitor 1. Standard deviation was obtained from more than 3 separate sets of 
experiments. 
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(E)VCR 
Fig 33.7 The effect of AG490 on drug induced D N A fragmentation. Cells were 
seeded for 3 days to sub confluence. Cells with or without co-incubation of drugs and 
AG490 were harvested after 72 h and subjected to D N A fragmentation assay. (A) 
Combined treatment with C A M and AG490. Lane 1: control; lane 2: treatment with 
25uM AG490; lane 3: treatment with 3ng/ml C A M ; lane 4: combined treatment with 
Sng/ml C A M and 25uM AG490 for 72 h. (B) Combined treatment with M T X and 
AG490. Lane 1: control; lane 2: treatment with 25uM AG490; lane 3: treatment with 
25nM M T X ; lane 4: combined treatment with 25 n M M T X and 25uM AG490 for 72 
h. (C) Combined treatment with T A M and AG490. Lane 1: control; lane 2: treatment 
with 25uM AG490; lane 3: treatment with 15uM T A M ; lane 4: combined treatment 
with 15uM T A M and 25uM AG490 for 72 h. (D) Combined treatment with T A X and 
AG490. Lane 1: control; lane 2: treatment with 25uM AG490; lane 3: treatment with 
15ng/ml TAX; lane 4: combined treatment with 15ng/ml T A X and 25uM AG490 for 
72 h. (E) Combined treatment with V C R and AG490. Lane 1: control; lane 2: 
treatment with 25uM AG490; lane 3: treatment with 3ng/ml VCR; lane 4: combined 
treatment with 3ng/ml V C R and 25uM AG490 for 72 h. The experiment was 
repeated for three times. The one shown is the most representative one. 
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3.3.6 Jak signaling and caspase activation in MTX induced apoptosis in Saos-2 
cells 
AG490 was able to modulate the Jak/Stat signaling, therefore the effect of the 
combined treatment of Saos-2 control cells and mutant p53 transfectant with M T X 
and AG490 on the Jak/Stat pathway was studied by Western blot analysis. The level 
of basal Jak2 phosphorylation was lower in the mutant p53 transfectants than that in 
the control cells. M T X and AG490, alone or in combination, seemed to suppress 
Jak2 phosphorylation in the control cells but slightly stimulate that in mutant p53 
transfectants. In mutant p53 transfectants, the stimulation effect by M T X and AG490 
appeared to be more significant when in combination. There was no Statl 
phosphorylation detected in all cells under the treatment of M T X and/or AG490. The 
basal Stat3 phosphorylation in mutant p53 transfectants is higher than that in the 
control cells. M T X and AG490, alone or in combination, appeared to downregulate 
Stat3 phosporylation in both Saos-2 control cells and mutant p53 transfectants. 
Futhermore, the significant inhibition of Stat3 phosphorylation was more obvious in 
Saos-2 control cells. (Fig. 3.3.8-9). 
The influence of AG490 on M T X induced apoptosis was further elucidated by 
Western blot analysis. M T X seemed to cause a caspase 3 cleavage at 48 and 72 h 
incubation in Saos-2 control cells and a slight cleavage in p53-R273H transfectnat 
but such change was not detected in mutant p53-V143A transfectant. There was a 
slight decrease in pro-caspase 9 level at 48 and 72 h M T X incubation in Saos-2 
control cells while that in mutant p53 transfectants appeared to remain unchanged. 
M T X seemed not to induce caspase 8 cleavage in all cells (Fig. 3.2.10). Thus, M T X 
induced apoptosis may involve caspase 3 and 9. The combined treatment of M T X 
and AG490 resulted in inhibition of the M T X induced caspase 3 cleavage as assessed 
by Western blot analysis in Saos-2 control cells. The effect seemed not so obvious in 
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mutant p53 transfectants due to the low level of caspase 3 cleavage in these cells (Fig. 
3.2.11). The effect of AG490 on M T X activation of caspase 3 was supported by 
caspase 3 catalytic activity assay. AG490 and M T X may both induce caspase 3 
catalytic activation while AG490 may suppress M T X induced caspase 3 activation in 
Saos-2 control cells while the effect is slight in mutant p53 transfectants as the basal 
caspase 3 activities were low in these cells (Fig. 3.2.12). This implicated that Jak2 
may play a role in M T X sensitivity through the caspase 3 activation. 
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Fig. 3.3.8 The effect of M T X and AG490 on JAK/STAT signaling pathway in Saos-2 
cells. Cells were seeded for 3 days to sub confluence. Cells with or without 
pretreatment of AG490 for 16 h was treated with M T X for 15 mins. Cells were lysed 
and resolved in SDS-PAGE, transferred to membranes and probed with specific 
antibodies. Signals were visualized under a X-ray film using the E C L system. Lane 1: 
control; lane 2: 16 hours preincubation with lOOuM AG490; lane 3: 15 minutes 
stimulation by 50nM M T X ; lane 4: 16 hours preincubation with lOOuM AG490 
followed by 15 minutes stimulation by 50nM M T X . 
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Fig 3.3.9 The effect of M T X and AG490 on specific phosphorylation of Jaks and 
Stats in Saos-2 cells. Cells were seeded for 3 days to sub confluence. Cells with or 
without pretreatment of AG490 was treated with M T X for 15 mins. Cells were lysed 
and resolved in SDS-PAGE, transferred to membranes and probed with specific 
antibodies. Signals were visualized under an X-ray film using the E C L system. The 
relative intensity is estimated by program Kodak Digital Science ID Scientific 
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Imaging System. The specific phosphorylation of the molecules was calculated by: 
band intensity of phosphorylated form of that protein / band intensity of total level of 
that protein. Relative specific phosphorylation was determined by with respect to the 
phosphorylation level in the control cells with control treatment: specific 
phosphorylation of a treatment / specific phosphorylation of control cells with 
control treatment. Lane 1: control; lane 2: 16 hours preincubation with lOOuM 
AG490; lane 3: 15 minutes stimulation by 50nM M T X ; lane 4: 16 hours 
preincubation with lOOuM AG490 followed by 15 minutes stimulation by 50nM 
1VITX. 
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Fig. 3.3.10 M T X induced caspase cascade activation. Sub confluent cells were 
treated with M T X at various times. Cells were lysed and resolved in SDS-PAGE, 
transferred to membranes and probed with specific antibodies. Signals were 
visualized under a X-ray film using the E C L system. The intensity of the protein 
band was quantified by program Kodak Digital Science ID Scientific Imaging 
System. The numerical value next to the protein band is the relative expression of the 
specific protein which is calculated as the ratio between the protein band intensity for 
a specific condition in relation to that for the control cells under control condition. 
Lane 1: control, lane 2, 3 and 4: 25nM M T X treatment for 24, 48 and 72 h 
respectively. 
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Fig. 3.3.11 The effect of AG490 on M T X induced caspase activation in Saos-2 cells. 
Cells after treatment of AG490, M T X or combined treatment of both were lysed and 
resolved in SDS-PAGE gel, transferred to a membrane and probed with specific 
antibody. Signals were visualized under a X-ray film using the E C L system. The 
intensity of the protein band was quantified by program Kodak Digital Science ID 
Scientific Imaging System. The numerical value next to the protein band is the 
relative expression of the specific protein which is calculated as the ratio between the 
protein band intensity for a specific condition in relation to that for the control cells 
under control condition. Lane 1: control; lane 2: treatment with 25uM AG490; lane 3: 
treatment with 25nM M T X ; lane 4: combined treatment with 25uM AG490 and 





Q Q t ! 
p53-V143A p53-R273H 
1.4 B � 
1.2 - 1-2 
1.0 1.0 
0.8 - 0.8 
0.6 0.6 
0.4 0.4 艮 ？di L 
I I 0.2 - 0.2 - • 




Fig. 3.3.12 The effect of AG490 on M T X induced caspase 3 catalytic activity. Cells 
after treatment of AG490, M T X or combined treatment of both were lysed and 
subjected to caspase 3 activity assay using colorimetric caspase 3 substrate 
Ac-DEVD-pNA. The relative caspase 3 activity was normalized by the basal caspase 
3 catalytic activity in Saos-2 control cells. Lane 1: control; lane 2: 25uM AG490 
treatment for 72 hour; lane 3: 25nM M T X treatment; lane 4; combined treatment 
with 25uM AG490 and 25nM M T X for 72 h. 
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3.3 Discussion 
3.3.1 Mutant p53-V143A and p53-R273H induced drug resistance in Saos-2 cells 
Multidrug resistance is one of the major obstacles in chemotherapy and cancer cells 
acquire drug resistance in the course of cancer treatment. The mechanisms of drug 
resistance attribute to the increased drug efflux and detoxification system, alterations 
of target genes, D N A repair genes and apoptosis and survival signaling, etc. However 
the predominant pathway seems to be cell type and drug specific. The determinant of 
the drug resistance is yet to be determined. 
Mutation in p53 gene is common in cancers and is associated with drug resistance 
through transactivation of genes like M D R l , dUTPase, and repression of 
Fas/CD95/Apol gene, etc (see chapter 1). In this study, the role of mutant p53 in 
drug resistance was elucidated. Saos-2 cells, with or without mutant p53 transfection, 
were used to see if mutant p53 would induce drug resistance. Cell proliferation M T T 
assay showed that cells transfected with mutant p53-V143A and p53-R273H were 
more resistant to camptothecin, methotrexate, tamoxifen and vincristine and 
p53-V143A also made the cells more resistant to taxol. This implicates that mutant 
p53 gains new functions in inducing multidrug resistance in Saos-2 cells. 
Mechanistic study showed that mutant p53 transfectants were more resistant to the 
C A M , M T X , T A M and V C R induced apoptosis and cell cycle arrest while mutant 
p53-V143A was more resistant to T A X induced apoptosis and cell cycle arrest. 
One of the mechanisms in drug resistance is the alteration of the target gene 
expression. Mutant p53 may be able to transregulate the expression of these targets 
and affect the drug sensitivity. Therefore, the expression levels of some of the 
classical drug targets were studied. Topoisomerase I is associated with C A M 
sensitivity, and dihydrofolate reductase and thymidine synthetase are involved in 
M T X sensitivity. Western blot analysis and RT-PCR showed that the expression 
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levels of topol, D H F R and TS were similar. Therefore, the mutant p53 induced drug 
resistance may not involve regulation of the target genes at least in the case of C A M 
and M T X . 
3.3.2 Role of Jaks in drug sensitivity in Saos-2 cells 
Some members in the Jak/Stat pathway would affect drug sensitivity by controlling 
drug induced apoptosis, for example Statl (Stephanou and Latcheman 2003) and 
Stat3 (Rebaa et al. 2001). Mutant p53 gains new function in regulating the expression 
of Jaks and Stats in Saos-2 cells and Jaks were found to regulate IFN sensitivity as 
discussed in previous chapter. Thus, mutant p53 transfectants may gain drug 
resistance through the regulation of Jak/Stat pathway. AG490, a Jak2 specific 
inhibitor, and Jak inhibitor I, a Janus kinase inhibitor, were used to study the role of 
Jaks in drug sensitivity of Saos-2 cells. AG490 made Saos-2 cells more resistant to 
M T X most significantly when compared to other drugs. This was further confirmed 
by Jak inhibitor I which also made the cells more resistant to M T X . Therefore Jaks 
are thought to play a role in M T X sensitivity. 
Mutant p53 transfectants were more resistant to drug induced apoptosis as mentioned 
before. To see if such resistance is related to Jaks in Saos-2 cells, combination 
treatment of drug and AG490 was applied. AG490 made the cells resistant to M T X 
induced D N A fragmentation while such modulation was not significant in other 
drugs. This agreed with the cell proliferation study that AG490 made Saos-2 cells 
resistant to M T X . It implicates that Jak2 may play a role in M T X sensitivity through 
drug induced apoptosis in Saos-2 cells. 
3.3.3 Jak/Stat signaling in Saos-2 cells 
Jak2 is the most upstream kinase in Jak/Stat pathway, the possible mechanisms by 
which Jak2 may involve in M T X sensitivity could be through its direct effect on 
Jak/Stat signaling and/ or apoptotic pathway. The phosphorylation status of Jak2 and 
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the downstream Stats, Statl, Stat3 and StatS, were studied. The basal Stat3 
phosphorylation was higher in mutant p53 transfectants than that in the control cells. 
Therefore, Stat3 phosphorylation may provide a pro-survival or anti-apoptotic 
signals to the cells. And this notion has been supported by other groups that Stat3 is 
involved in pro-survival and anti-apoptotic functions by regulating BC1-XL and 
survivin expression. However, AG490 seemed to further downregulate the Stat3 
phosphorylation in combination treatment with M T X and this failed to correlate with 
its effect on sensitivity of Saos-2 cells to M T X . That is, if Stat3 phosphorylation 
provides pro-survival or anti-apoptotic signals to the cells, combined treatment of 
M T X and AG490 should amplify such signals when compared with the treatment 
with M T X alone. Therefore, downregulation of Jak2 phosphorylation in mutant p53 
transfectants may correlate with M T X resistance. The basal Jak2 phosphorylation 
appeared to be lower in mutant p53 transfectants and AG490 suppressed Jak2 
phosphorylation alone or combined with M T X in Saos-2 control cells. Therefore, 
downregulation of Jak2 phosphorylation in mutant p53 transfectants may correlate 
with M T X resistance. However, the AG490 seemed to increase basal Jak2 
phosphorylation in p53-V143A and have no effect in p53-R273H. This may be 
because the basal Jak2 phosphorylation was low in these cells, the effect of AG490 
may seem minimal. 
3.3.4 Jak2 and MTX induced apoptosis 
Mutant p53 transfectant resistance to M T X might be mediated through resistance to 
M T X induced apoptosis. The role of Jak2 in such resistance was confirmed by the 
effect of AG490 on M T X induced D N A fragmentation. AG490 protected Saos-2 
control cells from M T X induced D N A fragmentation. The M T X mediated apoptosis 
involved activation of caspase 3. AG490 was able to inhibit M T X induced 
pro-caspase 3 cleavage and activation of catalytic activity of caspase 3. This 
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demonstrates that Jak2 was involved in mutant p53 mediated M T X resistance 
through caspase 3 activated apoptotic pathway. 
The present studies on the role of Jak2 in malignancies focus on its proliferation 
effect. Tel-Jak2 fusion protein is associated with acute lymphocytic leukemias and 
might induce simultaneously with StatS and Statl the constitutive activation of Stat3 
and promotes factor-dependent proliferation (Scwaller et al. 1998). Jak 
hyperactivation plays a role in human T cell leukemia vims I-transformed T cells 
(Migone et al. 1995), Sezary's syndrome (Zhang et al. 1996), v-abl-transformed cells 
(Danial et al. 1995) and acute lymphoblastic leukemia (Meydan et al. 1996). The 
present study suggests that new role for Jaks in drug sensitivity, especially in the case 
of Jakl. Jakl may modulate M T X sensitivity in Saos-2 cells through regulation of 
the apoptotic pathway. 
I l l 
Chapter 4 General discussion 
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There are different strategies in cancer treatment using different therapeutic agents 
including chemotherapy, radiotherapy, immunotherapy, etc. One of the major 
obstacles in cancer therapy is drug resistance. This phenomenon is common in 
recurred cancer or during cancer progression. There are many mechanisms proposed. 
They are enhanced drug efflux and detoxification, alterations in target gene and D N A 
repair gene expressions, and changes in apoptosis and survival signaling. Different 
mechanism seems to be important in different situation, like cell type, drug, 
environment of the cells, etc (Stavrovskaya 2000). There is lack of study on the 
underlying factor and molecular mechanism determining resistance to cancer therapy. 
This adds difficulty to cancer treatment and prognosis. 
The tumor suppressor p53 gene is mutated in over 50% of human cancers (Beroud et 
al. 1998; Hollstein et al. 1998; Hainaut et al. 2000). Many studies have been done on 
its wild-type functions as tumor suppressor in cell cycle arrest and apoptosis in 
response to various stresses (Lane 1992 and Levine 1997). Loss of wild-type p53 
functions contributes to genomic instability and facilitates cancer progression 
(Motoyama and Naka 2004). It is also associated with drug resistance (Vasey et al. 
1996; Blandino et al. 1999; Pugacheva et al. 2002; Soussi 2003; Zalcenstein et al. 
2003). On the other hand, mutant p53 has been reported to gain new functions by 
transregulating other genes. This usually accompanied with increased malignancy 
such as drug resistance. Therefore, the role of mutant p53 in immunotherapy and 
chemotherapy resistance was studied in human osteosarcoma Saos-2 cells which is a 
p53-null cell line transfected with control vector alone, vector carrying mutant 
p53-V143Aor p53-R273H. 
4.1 Mutant p53 induced immunotherapy and chemotherapy resistance 
Mutant p53-V143A and p53-R273H both gained new functions in making Saos-2 
cells more resistant to IFNs and common anticancer drugs through resistance to IFN 
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or drug induced apoptosis and cell cycle arrest. It was speculated that mutant 
p53-V143A and p53-R273H may transregulate genes that modulate the cellular 
response to the therapeutic agents. 
4.2 Gain of new function of mutant p53-V143A and p53-R273H in regulating 
Jak/Stat pathway leading to resistance to IFN and chemotherapeutic drugs 
As mutant p53 transfectants were found to be IFN resistant, the expression profile of 
signaling molecules in the IFN pathway, i.e. the Jak/Stat pathway, was studied. To 
our surprise, mutant p53-V143A and p53-R273H were able to regulate the 
expression of different Jaks and Stats with a general downregulation of the Jaks in 
which p53-V143A downregulated Tyk2 while p53-R273H downregulated Tyk2 and 
Jak2. Therefore, the regulation of Jak/Stat pathway seems to be mutant specific. 
Using Jak2 inhibitor, AG490, and Janus kinase inhibitor, Jak inhibitor I, the role of 
Jaks in IFN sensitivity was confirmed. By inhibiting Jaks, Saos-2 cells were made 
more resistant to IFNs but not through resistance to IFN induced apoptosis. 
W e further extended the study of Jaks to drug sensitivity and we are the first group to 
demonstrate that Jaks were involved in C A M , M T X and V C R sensitivity. The 
protection effect of AG490 was most significant in M T X treatment suggesting that 
Jak2 played a role in M T X sensitivity in Saos-2 cells. 
4.3 The role of Jaks in MTX sensitivity 
Jaks were found to be involved in IFN and drug sensitivity. The most significant 
effect observed in Saos-2 cells would be Jak2 in M T X sensitivity. Mechanistic 
studies revealed that inhibition of Jak2 protected the cells from M T X induced 
apoptosis through the inhibition of the caspase cascade involving caspase 3. The 
study on Jak/Stat signaling under M T X and AG490 treatment revealed that there was 
basal difference in phosphorylated form of Jak2 and Stat3: basal Jakl 
phosphorylation level was downregulated in mutant p53 transfectants; while basal 
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StatS phosphorylation and specific phosphorylation were upregulated in mutant p53 
transfectants. Other studies suggest that Jaks and Stats are involved in tumorigenesis. 
Statl, StatS and StatS play important role in controlling cell cycle progression and 
apoptosis and thus contributes to oncogenesis. Statl is considered to be a tumor 
suppressor since it plays a role in growth arrest and in promoting apoptosis. StatS and 
StatS are considered as oncogenes as they bring about the activation of cyclin Dl, 
c-Myc and BCI-XL expression (Sinibaldi et al. 2000; Martino et al. 2001; Calo et al. 
2003). But there are limited studies suggesting the role of Jaks and Stats in drug 
sensitivity. Statl cooperates with wild-type p53 to induce apoptosis in response to 
D N A damage (Stephanou and Latchman 2003; Townsend et al. 2004). Stat3 
activation is involved in doxorubicin resistance in human neuroblastoma possibly 
through expression of survivin and BC1-XL (Rebbaa et al. 2001; Konnikva et al. 2003). 
The present data suggest that Jaks could modulate drug sensitivity through regulation 
of the apoptotic pathway. However, the study on Jak/Stat signaling failed to provide 
hints for which Stat protein was involved in such modulation. Further 
characterization will be needed. And also, the present study implicates the role of 
Jak2 in drug sensitivity, but we found that p53-V143A and p53-R273H could 
regulate other Jaks and Stats like Tyk2, Statl, Stat5, etc. Their roles in drug 
sensitivity are left to be unveiled. Jak2 may be just one of the determinants in the 
Jak/Stat pathway controlling drug sensitivity in Saos-2 cells. 
4.4 Future work 
The role of mutant p53 in regulation of the Jak/Stat signaling molecules and drug 
sensitivity could originally be confirmed by gene specific knockdown by antisense 
oligonucleotide or siRNA transfection. However, successful gene knockdown using 
p53 antisense oligonucleotide and siRNA was hardly seen in Saos-2 cells although 
many different transfection conditions have been tested, for example, different cell 
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density, antisense olignucleotide, siRNA, transfection time, transfection agents, etc 
(Fig. 4.4.1-2). The possibility of technical problems were ruled out as knockdown of 
p53 by siRNA could be observed in another cell line, human squamous carcinoma 
A431 cells (Fig. 4.4.3). Therefore, other transfection method should be sought like 
electroporation in order to carry out the mutant p53 knockdown experiments. 
Jaks were involved in IFN, C A M , M T X and V C R sensitivity in Saos-2 cells, the role 
of each kinase should be characterized. The role of Jak2 in IFN and M T X 
sensitivities of Saos-2 cells was elucidated by the specific Jak2 inhibitor AG490. The 
role of other kinases could theoretically studied by gene specific knockdown or 
transfection. Although a Tyk2 siRNA has been designed and found to be effective in 
A431 cells, it was found not to have effect in Saos-2 cells due to the difficulties in 
transfection as discussed above (Fig. 4.4.4). 
Jak2 played a significant role in IFN and M T X sensitivity. Its role in IFN resistance 
seemed to be unrelated to IFN induced apoptosis. Therefore, it should further be 
characterized for instance by cell cycle analysis. Jak2 mediated M T X sensitivity 
through the apoptotic pathway involving caspase 3, The downstream effectors of 
Jak2 through which it controlled the M T X sensitivity should be elucidated. The 
possible candidate would be Stat3 although the signaling under M T X and AG490 
indicated that Stat3 did not correlate with the M T X sensitivity. Experiments should 
be done to characterize the kinetic effect of M T X and AG490 on the Jak/Stat 
pathway. 
Mutant p53 could transregulate the expressions of Jaks and Stats possibly through 
regulation at the transcriptional level. This could be confirmed by using RT-PCR to 
compare the m R N A levels of these proteins in Saos-2 cells control cells and mutant 
p53 transfectants. 
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Fig. 4.4.1 The effect of p53 antisense oligonucleotides on Saos-2 protein expression. 
Cells were seeded for 24 h at desired cell density. Cells were transfected with p53 
antisense oligonucleotides complementary to the coding region of p53 m R N A with 
the sequence 5，-CCCTGCTCCCCCTGGCTCC-3, using oligofectamine (Invitrogen, 
HK). Cells were lysed and probed for p53. (A) Cells with or without transfection of 
200nM oligonucleotides were lysed immediately for Western blot analysis after 4 h 
of transfection. Lane 1: cells without transfection; lane 2: cells transfected with sense 
oligonucleotides of which the sequence is in complementary to the antisense 
sequence; Lane 3: cells transfected with the antisense oligonucleotides. (B) Cells 
with or without transfection of 200nM oligonucleotides were lysed at 24 h after 
transfection. Lane 1: cells without transfection; Lane 2: cells transfected with sense 
oligonucleotides of which the sequence is in complementary to the antisense 
sequence; Lane 3: cells transfected with the antisense oligonucleotides. (C) Cells 
with different cell denstities were transfected with 200nM oligonucleotides. Cells 
were lysed 24h after transfection. Lane 1: cells without transfection; Lanes 2, 3 and 4: 
cells with 1 X 10^ 1.5 x 10^ and 2 x 10^ were seeded on 3 5 m m dish for transfection 
respectively. 
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Fig. 4.4.2 The effect ofp53 siRNA on Saos-2 protein expression. Cells were seeded 
for 24 h and transfected with p53 siRNA vector encoding for the hairpin sequence of 
p53 siRNA. The target sequence of the p53 siRNA was 
5 ' - A A T G G T T C A C T G A A G A C C C A G . Cells were lysed 24 h after transfection for 
protein analysis and probed for p53. (A) Cells were transfected with different amount 
of p53 siRNA using lipofectainine2000 (Invitrogen, HK). Lane 1: cells without 
transfection; Lanes 2, 3, 4 and 5: cells transfected with 1, 5, 10 and 100 n M p53 
siRNA respectively. (B) Cells were transfected with different amount of p53 siRNA 
using GeneJuice (Novagen, Inc.). Lane 1: cells without transfection; Lanes 2, 3 and 4: 
cells transfected with 0.5, 1 and 1.5 ug siRNA respectively. 
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Fig. 4.4.3 The effect of p53 siRNA on the protein expression of A431 cells. Cells 
were seeded for 24 h and transfected with p53 siRNAi using oligofectamine. Cells 
were lysed 24 h after transfection and probed for p53. Lane 1: cells without 
transfection; Lanes 2 and 3: cells transfected with 10 and lOOnM p53 siRNA. 
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Fig. 4.4.4 The effect ofTyk2 siRNA on Tyk2 expression in Saos-2 and A431 cells. 
Cells were seeded for 24 h and transfected with Tyk2 siRNA. Cells were lysed 24 h 
after transfection for proteins and probed for Tyk2. Lane 1: cells without transfection; 
Lanes 2 and 3: cells transfected with 10 and 100 n M siRNA respectively. 
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4.5 Perspective 
There are different strategies in overcoming drug resistance in cancer including 
suppressing the proteins that inhibit apoptosis or targeting at proteins that modulate 
apoptosis, modulating glutathione level, inhibiting the P-gp function, etc. Another 
strategy is to target at the signaling pathway that is involved in drug sensitivity. One 
promising agent is the use of Gleevec (STI571) in treating chronic myelogenous 
leukemia (CML) with the presence of the Philadelphia chromosome, a reciprocal 
translocation between chromosomes 9 and 22 in the blast cells. The resulting 
Bcr-Abl fusion protein loses its normal regulation of Abl kinase activity and renders 
myeloid cells proliferation independent of growth factor. STI571 competes with ATP 
for its binding site on the Abl kinase molecule. By blocking this constitutive kinase 
signal, STI571 is able to downregulate BC1-XL and induce apoptosis (Horita et al. 
2000). The success of STI571 is due to the elucidation of the factors determining 
drug sensitivity of the C M L cells. Therefore, characterization of the signals 
controlling drug sensitivity in human cancers is important for discovery of new target 
for cancer treatment. In this study, it is discovered that mutant p53-V143A and 
p53-R273H regulated the Jak/Stat signaling molecules and in turn Jaks and Stats 
were involved in sensitivity to some therapeutic agents like IFNs and M T X that may 
in turn control the apoptotic pathway. This sheds new light on the possible targets for 
modulation of drug sensitivity, individualized chemo- or immunotherapy and 
prognosis of treatment for patients carrying particular p53 mutation. 
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